

1 **Title:** Paving the way for human vaccination against Rift Valley fever virus:

2 A systematic literature review of RVFV epidemiology from 1999 to 2021

3

4 **Short Title:** Review of RVFV epidemiology for a human vaccination trial

5 **Authors:** Keli N. Gerken¹, A. Desirée LaBeaud¹, Henshaw Mandi², Maïna L’Azou

6 Jackson³, J. Gabrielle Breugelmans², Charles H. King^{4*}

7 ¹Division of Pediatric Infectious Diseases, Department of Pediatrics, Stanford University

8 School of Medicine, Stanford, California, USA

9 ²Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway

10 ³Coalition for Epidemic Preparedness Innovations (CEPI), London, UK

11 ⁴Center for Global Health and Diseases, Department of Pathology, Case Western

12 Reserve University School of Medicine, Cleveland, Ohio, USA

13

14 Word count, abstract: 332

15 Word count, manuscript: 11402

16 Tables: 3 (13 supplementary)

17 Figures: 10 (3 supplementary)

18

19 *Corresponding author:

20 Email: charlesking48@gmail.com (CHK)

21

22

23 **Abstract**

24 **Background:** Rift Valley fever virus (RVFV) is a lethal threat to humans and
25 livestock in many parts of Africa, Arabia, and the Indian Ocean. This systematic review's
26 objective was to consolidate understanding of RVFV epidemiology during 1999-2021
27 and highlight knowledge gaps relevant to plans for human vaccine trials.

28 **Methodology/Principal Findings:** The review is registered with PROSPERO
29 (CRD42020221622). Reports of RVFV infection or exposure among humans, animals,
30 and/or vectors in Africa, the Arabian Peninsula, and the Indian Ocean during the period
31 January 1999 to June 2021 were eligible for inclusion. Online databases were searched
32 for publications, and supplemental materials were recovered from official reports and
33 research colleagues. Exposures were classified into five groups: 1) acute human RVF
34 cases, 2) acute animal cases, 3) human RVFV sero-surveys, 4) animal sero-surveys,
35 and 5) insect infections. Human risk factors, circulating RVFV lineages, and surveillance
36 methods were also tabulated. In meta-analysis of risks, summary odds ratios were
37 computed using random-effects modeling. 1104 unique human or animal RVFV
38 transmission events were reported in 39 countries during 1999-2021. Outbreaks among
39 humans or animals occurred at rates of 5.8/year and 12.4/year, respectively, with
40 Mauritania, Madagascar, Kenya, South Africa, and Sudan having the most human
41 outbreak years. Men had greater odds of RVFV infection than women, and animal
42 contact, butchering, milking, and handling aborted material were significantly associated
43 with greater odds of exposure. Animal risk was linked to location, proximity to water,
44 and exposure to other herds or wildlife. RVFV was detected in a variety of mosquito
45 vectors during interepidemic periods, confirming ongoing transmission.

46 **Conclusions/Significance:** With broad variability in surveillance, case finding,
47 survey design, and RVFV case confirmation, combined with uncertainty about
48 populations-at-risk, there were inconsistent results from location to location. However, it
49 was evident that RVFV transmission is expanding its range and frequency. Gaps
50 assessment indicated the need to harmonize human and animal surveillance and
51 improve diagnostics and genotyping. Given the frequency of RVFV outbreaks, human
52 vaccination has strong potential to mitigate the impact of this now widely endemic
53 disease.

54

55 **Author Summary**

56 Rift Valley fever virus (RVFV) is a globally important mosquito-transmitted
57 zoonosis that is also directly transmissible via aerosolization of body fluids from infected
58 animals. RVFV outbreaks cause mass mortality of young livestock and pregnancy
59 losses in both humans and animals. Severe human cases also result in hemorrhagic
60 fever, encephalitis, and death. Loss of livestock additionally threatens the livelihood of
61 people who depend on animals for income and food. In endemic areas, initiation of
62 RVFV outbreaks is connected to weather events that cause excess rainfall, leading to
63 flooding and subsequent mosquito blooms. However, the natural cycle of RVFV
64 transmission is complex, requiring congregation of susceptible mammalian hosts and
65 mosquito vectors in suitable environments. Several human vaccine candidates are in
66 different stages of development, but none are yet licensed for use in human
67 populations. In this systematic review, we assessed the 1999-2021 frequency and
68 distribution of RVFV outbreaks among humans, animals, and vectors to identify

69 potential locations and population targets for a human RVFV vaccine efficacy trial. It
70 focuses on current understanding of RVFV epidemiology and the identification of gaps
71 that pose critical barriers to controlling expansion of RVFV and implementing new
72 protective measures including human vaccination.

73

74

75 **Introduction**

76 Rift Valley fever virus (RVFV) remains an important emerging arboviral pathogen
77 due to its recent geographic spread and its combined disease and financial impacts on
78 vulnerable human populations [1]. Specifically, RVFV is listed as a priority pathogen by
79 the World Health Organization (WHO), the Food and Agriculture Organization of the
80 United Nations (FAO), and the U.S. Centers for Disease Control and Prevention (CDC)
81 because of its ability to cause life-threatening hemorrhagic fever and encephalitis in
82 humans [2, 3], its epidemic potential to cause severe harm to livestock [4, 5], and its
83 potential for non-vector aerosol spread during epizootics and epidemics [6, 7]. The RVF
84 virus is a member of the *Phlebovirus* genus, with three main lineages, with East African,
85 West African, and Southern African groupings.

86 RVFV was first identified in 1931 during an investigation into an epidemic of
87 fatalities among sheep on a farm in the Rift Valley Province of Kenya [8]. Since that
88 time, its spatial range has continued to expand from East Africa into southern Africa,
89 West Africa, and North Africa, and more recently outside Africa to the Arabian Peninsula
90 [6, 7, 9]. RVFV can infect a wide range of mammalian hosts [10] and can be carried by
91 many insect vectors. Floodwater *Aedes spp.* are important in maintenance during

92 interepidemic periods, whereas other Diptera serve as secondary vectors during
93 outbreaks in sub-tropical and temperate regions of the world [11-15]. RVFV results in
94 lower case fatality rates (CFR) compared to other hemorrhagic fever viruses [4], but its
95 outbreaks have profound compounding effects on human subsistence (from loss of
96 livestock) and on national economies, related to livestock export bans [16-19].

97 The critical environmental reservoir of RVFV is presently unknown. Humans
98 become infected either through the bite of an infected vector or through exposure to
99 infectious animal tissues or bodily fluids such as abortus, birthing fluids, meat, milk, or
100 blood aerosolized during slaughtering. Other than *in utero* transmission, there is no
101 evidence for human-human transmission of RVFV [4]. Those infected either remain
102 minimally symptomatic or develop a mild form of the disease Rift Valley fever (RVF)
103 (96% of patients), which is characterized by a febrile syndrome with sudden onset of flu-
104 like fever, muscle pain, joint pain, and headache [4]. Some patients develop neck
105 stiffness, sensitivity to light, loss of appetite and vomiting and therefore RVF can be
106 mistaken for meningitis [20]. While most human cases are relatively mild, a small
107 percentage of patients will develop a much more severe form of the disease [21]. This
108 usually appears as one (or more) of three distinct syndromes: ocular (eye) disease
109 (0.5–2% of patients), meningoencephalitis (fewer than 1% of patients) or hemorrhagic
110 fever (fewer than 1% of patients) [4].

111 Equally important is the lethal threat to peoples' livestock. RVFV spread into
112 naïve ecosystems is driven by infected animal movement and potentially via infected
113 vectors [22], and can result in death of between 70-90% of young ruminants with sheep
114 the most affected, and loss of pregnancy in nearly 100% of pregnant animals [23].

115 Outbreaks in humans and in animals do not occur at random. Instead they are
116 strongly linked to excess rainfall and to local flooding events [24] and the consequent
117 rise in mosquito abundance [25-32]. In addition, there is mounting evidence that
118 suggests that there is continuing low-level RVFV transmission to humans and to
119 animals between recognized epidemic periods [33-49]. Undetected infections,
120 particularly in livestock, provide an important reservoir for recurrent outbreaks, leading
121 to a continuing threat of disease in economically marginal communities and risk of
122 further geographical expansion.

123 The specific objective of this study was to consolidate the understanding of
124 recent RVF epidemiology over the recent 1999-2021 period. We sought to catalogue
125 the variability of national/regional incidence and prevalence, human risk factors and
126 populations at risk, the geospatial distribution of RVF serotypes/lineages, and the
127 present day national and regional human and animal RVF/viral hemorrhagic fever
128 surveillance systems. The systematic review also highlighted current knowledge gaps in
129 RVFV epidemiology to establish the major challenges remaining for current efforts in
130 development and testing of human vaccine.

131

132 **Methods**

133 To meet our study goals, we performed a systematic review of the available
134 published literature as well as governmental monitoring and media reports of RVF
135 activity during the period 1999-2021. The study results are reported according to the
136 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA
137 2020) guidelines [50]. See S1 Table for details.

138 **Inclusion/exclusion criteria.** Studies included in the review were those that
139 contained reports of human, animal, and/or vector RVFV infection or exposure among
140 individuals (of any age) in countries across Africa, the Arabian Peninsula, and the Indian
141 Ocean where RVFV transmission was detected during the period January 1st 1999 to
142 June 1st 2021, including historical, observational, and prospective studies. Serosurveys
143 from outside this target area (Spain [51, 52], Poland [53], Korea [54], and Jordan [55])
144 were also catalogued, although not formally included in our analysis. Reports containing
145 primary human seroprevalence or incidence data, reported RVF outbreaks or cases,
146 details of RVF transmission, RVFV lineage distribution, and/or risk factors were
147 included. Reports of infections among regional livestock and wildlife during the same
148 period were also included.

149 The primary objective was to obtain population-based survey data. However,
150 georeferenced location-specific case reports were also included in spatiotemporal
151 analysis. There was no restriction according to the language of publication.

152 Excluded studies were those that reported laboratory-based studies or
153 intervention trials among experimental animals in controlled settings. Reports, reviews,
154 or opinion articles without primary data were also excluded.

155 **Information sources and search strategy.** To maximize detection of eligible RVFV
156 transmission studies, we searched the online databases PubMed, Web of Science,
157 African Journals Online, The Cumulative Index to Nursing and Allied Health Literature
158 (CINAHL), The Scientific Electronic Library Online (SciELO), Elsevier, ResearchGate,
159 and the Program for Monitoring Emerging Diseases (ProMED) listserv site. Animal
160 outbreak data recorded by the World Organization for Animal Health (OIE) was

161 recovered from their databases, the 2005-2021 WAHIS (<https://wahis.oie.int/#/home>),
162 and the older Handistatus II database (<https://web.oie.int/hs2>). Other sources of papers
163 and reports that were also retrieved included: i) polling colleagues involved in RVF
164 research or control for any non-indexed 'grey literature', ii) using Google Scholar
165 referrals for 'similar papers', iii) scanning of literature found in personal archives, and iv)
166 obtaining non-indexed citations found among the reference lists of the papers reviewed
167 in our study. Unpublished data from a recent survey study in Nigeria was also included
168 (Bonto Faburay and colleagues, personal communication). Details of the information
169 sources and search strategy used are available in S1 Text.

170 **Selection process.** Review of titles and abstracts was performed by two trained
171 reviewers who independently searched for data content meeting study requirements.
172 The studies found potentially suitable for inclusion after title-abstract review were then
173 obtained for full-text review from online or library sources. Where a single report
174 contained data on multiple individual community surveys, each of these surveys was
175 separately abstracted and given a unique ID number for inclusion in sub-group
176 comparison analyses. Studies with insufficient details of the incidence or prevalence of
177 RVFV infection were not included, and cases of duplicate publication or extended
178 analysis of previously published data were removed from the list of selected references
179 for this review. Full listings of included and excluded references are provided as
180 Supporting Information files S2 and S3 Tables.

181 **Data collection process.** Included papers were abstracted by two independent
182 reviewers, and their relevant features entered into a purpose-built database created with
183 Google Forms. The entries were then stored in a shared master spreadsheet in Google

184 Sheets. The included papers and data registry downloads were archived in electronic
185 text (pdf) or spreadsheet formats at the Department of Pediatrics, Stanford University
186 School of Medicine, and at the Center for Global Health and Diseases, Case Western
187 Reserve University.

188 **Data items.** For the human and animal RVFV exposures or clinical cases reported,
189 information was entered into the database based on UN geographic region
190 (<https://unstats.un.org/unsd/methodology/m49>), country, and the sub-national
191 administrative location details that were reported. Islands in the Indian Ocean, normally
192 classified as 'Eastern Africa' by the UN, were grouped separately for our analyses. The
193 beginning and ending month and year of the reported RVF activity or exposure study
194 were recorded, as well as information about whether the event was a recurrence of
195 transmission in a previously affected area, whether there had been flooding before the
196 event, and whether the period involved an El Nino-Southern Oscillation (ENSO) event.
197 When outbreaks spanned more than one calendar year, the year of onset was used to
198 classify the event. Study design and the eligible study population were recorded for
199 each report and whether the report involved human cases, domestic or wildlife animals,
200 or insect vectors, and the number of affected individuals by species. Where available,
201 age and gender distributions were captured for both animal and human studies, along
202 with any potential risk factors that were studied, and which were found to be significant
203 by that study. Factors evaluated for human exposure risk were age and age class,
204 gender, occupation, socio-economic status, and participation in the animal care
205 activities of feeding, herding, sheltering, or milking livestock, as well as assisting birth,
206 butchering, or skinning, and disposal of aborted material, or consumption of raw milk.

207 Factors evaluated for animal RVFV exposure were age and age class, sex, breed, body
208 condition, herd size, grazing strategy, and environmental conditions including proximity
209 to water, local vegetation, rainfall, and mosquito control measures. Our data extraction
210 tool was designed to capture factors related to the area the animal was raised (water
211 sources nearby, mosquito exposures, rainfall, vegetation), herd factors (grazing
212 strategy, mosquito control measures, herd size) and individual risk factors such as body
213 condition and breed. In some animal studies, the age of the animal (by dental
214 examination) and sex could be objectively assessed at the time of sampling. We
215 grouped common animal exposures and determined how many studies had assessed
216 for the risk factor and how many individual studies found statistically significant results
217 by bivariate or multivariate analyses. Not all studies separated the species of animals
218 involved within each exposure, and these have been reported as “not subdivided by
219 species.” Information was recorded on the diagnostic tests used to identify acute cases
220 or exposures, and on each study’s criteria used to identify suspected and confirmed
221 animal or human cases of RVF. Available information regarding local RVF surveillance
222 methods was noted, as well as any information about the RVFV lineage involved in the
223 reported cases. Where individual outbreaks were reported in more than one publication
224 or governmental bulletin, case numbers and mortality for that outbreak were taken from
225 the latest reports.

226 **Study risk of bias assessment.** We used an abridged version of the Liverpool Quality
227 Appraisal Tool (LQAT) [56, 57] to assess study quality and risk of bias of included
228 studies because of the tool’s flexibility in accommodating different study designs and in
229 creating potential bias assessments specific to our diverse set of studies. Scoring

230 involved assessment of possible subject selection bias, response bias, follow up bias,
231 bias in risk factor assessment, bias in outcome assessment, or possible bias in
232 reporting the outcome. Scoring also included whether the study's analysis involved
233 adjustment for potential confounders. The LQAT score, combined with recorded
234 information about study design and power, were used to classify reports as weak (score
235 1-5), moderate (score 6-8), or strong evidence (score 9 or 10) regarding local risk for
236 disease or exposures. Each study was assessed independently by two reviewers with
237 discrepancies resolved in consultation with a third reader.

238 **Effect measures.** We enumerated the cumulative number of outbreaks reported within
239 national and sub-national borders over time, and the observed incidence or period
240 prevalence by location. However, because of significant heterogeneity created by
241 reporting bias, relative risk comparisons among the multiple locations were considered
242 unreliable. Continent-wide RVF risk assessment for Africa, based on climate, weather,
243 population, and landscape factors has been recently well studied [58-63] and so was
244 not repeated here. We have, however, updated prior meta-analysis assessment [64] of
245 individual human risk factors to provide evidence regarding specific sub-groups who
246 might serve as suitable high-risk subjects for a human vaccine trial. Because the
247 chances of infection were based on post hoc determination of exposures, summary
248 odds ratios, derived by random effects statistical modeling, were used to determine the
249 strength of these associations in the meta-analysis.

250 **Synthesis methods.** Outbreaks and exposures were classified into five groups: 1)
251 acute human RVF cases, 2) acute animal cases, 3) human RVFV exposure data (based
252 on sero-surveys), 4) animal exposure data, and 5) insect infection data. These were

253 tabulated over time and space using frequency measures and geo-located, when
254 necessary, using Google Earth Pro software (available at
255 <https://www.google.com/earth/versions/>). The two decades of inclusion (1999-2010 and
256 2001-2021) were assessed jointly and then separately to determine the evolution of
257 disease, changes in detection of disease through improved diagnostics, and the effects
258 of more robust surveillance. Regional maps at the national and sub-national level were
259 then prepared using QGIS software (<https://www.qgis.org/en/site/>) using base maps
260 supplied by the Database of Global Administrative Areas (GADM) (version 3.4, (April
261 2018, www.gadm.org, licensed for non-commercial purposes). Surveillance systems in
262 animals, humans, and vectors were categorized either as early warning systems,
263 detection in hospital-based surveys, use of sentinel herds for surveillance, or farmer
264 reported syndromic surveillance. For meta-analysis of individual human level risk
265 factors, results from those included studies with relevant human exposure data were
266 entered into Comprehensive Meta-Analysis software, v.3 (CMA, Biostat, Englewood,
267 NJ) for calculation of pooled summary estimates of exposure effects, along with their
268 confidence intervals. Heterogeneity levels were scored using Higgins's and Thompson's
269 I^2 statistic [65]. Summary estimates of intervention effects were computed using Der
270 Simonian and Laird random-effects modeling [66] implemented by the CMA software.
271 Summary data were presented visually by Forest plots showing the respective odds
272 ratio and 95% confidence interval ($CI_{95\%}$) for the pooled analysis. Assessment for
273 potential publication bias was carried out by visual inspection of funnel plots, and
274 statistically by calculating the Egger test. To explore heterogeneity and factors that
275 could potentially modify the summary estimates of effect, we performed subgroup


276 analyses stratified by study risk of bias, and by year of publication. For the sensitivity
277 analysis, each meta-analysis was retested with the exclusion of one study at a time to
278 assess the possibility of a disproportionate impact of any individual study on summary
279 estimates.

280

281 **Results**

282 **Studies and RVFV reports selected for inclusion**

283 Initial screening of online publication databases yielded 7097 listings for RVF or RVFV
284 during the period January 1999-June 2021 for our initial review (Fig 1). These were
285 supplemented by 771 georeferenced outbreak case reports obtained from OIE
286 databases World Animal Health Information System (WAHIS,
287 <https://wahis.oie.int/#/home>) for events after 2004, and from OIE Handistatus II
288 (<https://web.oie.int/hs2/report.asp?lang=en>) for earlier 1999-2003 events. Other
289 sources, including private archives, governmental reports, ProMed listings, listings from
290 previous systematic reviews [64, 67], and non-indexed citations (found in Google
291 Scholar and in bibliographies of papers under review), provided an additional 667
292 reports for consideration for possible inclusion. After removal of duplicates, 1976 unique
293 articles or reports were selected for full text review. After the full text review was
294 performed, 285 events reported in 281 publications, plus the 771 events identified in
295 OIE databases and 48 from grey literature, identified a total of 1104 unique human or
296 animal RVFV transmission events for inclusion in the analysis.



297

298 **Fig 1. PRISMA systematic review flow diagram of data collection and evaluation**

299 Online searches for publications and data registers (left side flow) were supplemented
300 by governmental outbreak reports, non-indexed citations found in local archives, and
301 citations found within the reference lists of the papers that were reviewed (right side
302 flow). Data from one unpublished study were also included for evaluation.
303

304 **Report characteristics**


305 Of the 285 included reports selected from the published literature, 91% were in peer-
306 reviewed journals, 7% were in governmental reports, and 2% were in abstracts or
307 published correspondence. Following the regional designations of the United Nations,
308 43% of these papers reported RVF activity in East Africa, 13% in West Africa, 13% in
309 the Arabian Peninsula, 10% in North Africa, and 10% in Southern Africa. The countries
310 of Kenya (n= 42 reports), Saudi Arabia (n= 32), Tanzania (n = 24), South Africa (n= 22),
311 Madagascar (n= 14), Sudan (n= 13), Mauritania (n= 11), and Mozambique (n= 11) were
312 the most frequent subjects of RVF outbreak reports and surveys. Thirty percent of
313 reports documented acute outbreaks (epidemics/epizootics), 61% were exposure
314 studies performed during interepidemic periods, and 7% were post-epidemic survey

315 studies. One hundred sixty-five (58%) were cross-sectional surveys of humans or
316 animals, 60 (21%) were acute case series, 35 (12%) involved prospective cohorts, and
317 4 (1%) were case-control studies. Forty-two (15%) reported on vector testing in affected
318 areas. Among published studies, 195 (68%) were non-randomized, 79 (28%) involved
319 some form of random sampling, and 11 (4%) did not clearly indicate how sampling was
320 done. In terms of study quality, the median LQAT score for published studies (where
321 higher scores indicated higher quality studies) was 6 (range = 2-11, IQR 5-7), meaning
322 the majority of studies had moderate-to-high risk of bias in assessing risk by location or
323 by sub-population. Details of all included studies, including individual risk-of-bias scores
324 are provided in S2 Table.

325 **Where RVFV transmission or RVF epidemics/epizootics occurred, 1999-2021**

326 Overall, 39 countries had evidence of RVFV circulation in humans, animals, or
327 vectors during the 1999-2021 period, based on detection of probable or confirmed acute
328 cases, positive PCR testing, or serosurvey results (Fig 2 and S4 Table). Eighty-three
329 reports documented 124 locations in 19 countries that had 4,353 probable or confirmed
330 acute human RVF cases and 755 deaths (Fig 3), whereas 107 reports documented
331 acute RVF animal events (470 OIE confirmed cases) in 31 countries between 1999 and
332 2021 (Fig 4). The median year of reported events was 2010. Outbreaks of clinical
333 disease among humans or animals occurred at average rates of 5.8/year and 12.4/year,
334 respectively, with Mauritania, Madagascar, Kenya, South Africa, and Sudan having the
335 most human outbreak years. When month of onset was given for acute outbreaks
336 reports (epizootics or epidemics), in East Africa, 77% (27/35) of outbreaks began
337 between November and January; for southern Africa, 80% (8/10) began between March


338 and June; for West Africa, 92% (12/13) began between July and October; for the
339 Arabian Peninsula, 93% (13/14) began between August and October; and for North
340 Africa, 67% (6/9) began between September and October.



341
342 **Fig 2. Regional map of countries exposed to RVFV infection based on findings of**
343 **studies included in the systematic review.** Countries were categorized as to whether
344 there was evidence of human, animal, or insect RVFV infection during the 1999-2021
345 era.
346

347 Maps in Figs 3 and 4 show the sub-national administrative regions where acute
348 human and animal cases were reported during the earlier (1999-2010) or latter (2011-
349 2021) halves of our study period, or both. The countries with multiple repeated human
350 outbreaks across both early and later time intervals were Kenya (n=4), Mauritania (n=5),
351 South Africa (n= 4) and Madagascar (n= 2). S5 Table lists dates, place names, GPS


352 locations, reported human case counts, incidence rates per 100,000, reported numbers
353 of deaths, and estimated case fatality risks.



354

355 **Fig 3. Sub-national administrative regions experiencing acute human cases of**
356 **RVF during the years 1999-2021** Locations are shaded according to whether they
357 experienced outbreaks before or after 2011, or if they had outbreaks during both
358 periods.
359

360 In terms of epizootic activity, Fig 4 highlights the countries that experienced repeated
361 acute RVF outbreaks among animals during one or both decades of the 1999-2021
362 period. These were Kenya (n= 4), Madagascar (n= 2), Mauritania (n= 6), Mayotte (n=
363 2), Mozambique (n=2), Senegal (n=3), and South Africa (n=4).



364

365 **Fig 4. Sub-national administrative regions experiencing acute animal cases of**
366 **RVF during the years 1999-2021** Locations are shaded according to whether they
367 experienced outbreaks before or after 2011, or during both periods of time.
368

369 **Serosurveys of human and animal RVFV exposure**

370 Of the population surveys performed during interepidemic periods to detect
371 evidence of prior local RVFV circulation, 50 surveyed human populations, 79 surveyed
372 livestock populations, and 23 tested local wild animals. Of these, eight jointly surveyed
373 both humans and livestock, and nine surveyed both wildlife and livestock. A summary of
374 available diagnostic assays used to identify anti-RVFV antibodies is presented below in
375 Table 1.

376

377

378 **Table 1. Currently used serologic assays for detection of RVFV exposure in**
 379 **humans.**

<i>In-house Methods</i>			
Method	Publication	Target antibody	Brief description
ELISA ¹	LaBeaud et al. 2008 [68]	IgG	Indirect ELISA for presence of anti-RVFV IgG antibodies at Stanford University School of Medicine using inactivated MP-12 strain for coating antigen. Validated in humans
ELISA DIVA ^{1,2}	McElroy et al. 2009 [69]	IgM or IgG	Two parallel ELISA to distinguish naturally infected from vaccination. Validated in goat and humans. Does not distinguish IgG vs IgM
ELISA ¹	Paweska et al. 2005 [70]	IgM and IgG	IgG sandwich and IgM capture assay that uses irradiated whole virus for antigen. Validated in humans
ELISA ¹	Paweska et al. 2007 [71]	IgG	Antigen made using recombinant N protein. Validated in humans
ELISA ¹	Jansen Van Vuren and Paweska, 2009 [72]	IgM and IgG	Indirect ELISA for IgG and IgM separately. Antigen made using recombinant N protein. Validated in humans
VNT ³	Winchger Schreur et al. 2017 [73]	All neutralizing antibodies	Uses a virulent RVFV that expresses enhanced green fluorescent protein. Not species specific
Optical Fiber Infrasond Sensor	Sobarzo et al. 2007 [74]	IgG	Sandwich based ELISA and antigens are immobilized on an optical fiber that makes it more sensitive. Validated in humans
Luminex DIVA ²	Van der Wal et al. 2012 [75]	IgM and IgG	Bead based assay that detects RVFV Gn and N proteins
<i>Commercially available methods</i>			
	Manufacturer		
IFA ⁴	EUROIMMUN	IgG	Approved for clinical testing
IFA ⁴	EUROIMMUN	IgM	Approved for clinical testing
ELISA ¹	Biological Diagnostic Supplies Limited	IgM and IgG	Approved for clinical testing

ELISA ¹	ID-Vet	IgG	Competitive ELISA kit for the detection of anti-RVFP antibodies in serum or plasma. Multi-species that includes human validation
ELISA ¹	ID-Vet	IgM	IgM Antibody Capture ELISA for the detection of anti-nucleoprotein IgM antibodies. Validated for ruminant serum and plasma

380 ¹ELISA: enzyme-linked immunoassay ²DIVA: Differentiating Infected from Vaccinated
381 Animals ³VNT: Viral neutralization test; ⁴IFA: immunofluorescent antibody

382

383 Adapted from Petrova, et al., BMJ Glob Health 2020,doi:10.1136/bmjgh-2020-002694
384 [76] under Creative Commons CC BY-NC

385

386 In several animal surveys performed during interepidemic periods, low rates of
387 livestock and wildlife anti-RVFP IgM seropositivity or IgG seroconversion were detected
388 in areas of Namibia, Senegal, South Africa, and Kenya [47, 77-79] suggesting
389 unsuspected ongoing RVFP transmission in those locations without detection of
390 concurrent clinical RVF cases. Also of note were animal studies that showed serologic
391 evidence of RVFP circulation among animals or humans within areas that had no prior
392 evidence of RVFP circulation. These were: among animals only, in Libya [OIE], Tunisia
393 [80], and Western Sahara [81] in North Africa, but in either humans or animals in Sierra
394 Leone [36], Côte d'Ivoire [82], Djibouti [83], Rwanda [84, 85], and eSwatini [OIE], i.e.,
395 geographical areas in sub-Saharan Africa with no previously documented transmission.
396 Anti-RVFP antibody testing of human patients in health centers in Ghana [86] and
397 Jordan [55] did not detect evidence of local exposure.

398 **RVFP lineage studies**

399 Twenty-six papers reported on sequence analysis of RVFP isolates from recent
400 and more distant outbreaks in an attempt to identify the geographic extent of specific
401 viral lineages in circulation at the time. Although variants have been seen to cluster in

402 East African, West African, and Southern African groupings, the results from different
403 studies are heterogeneous, and nomenclature for these variants has not yet been
404 standardized. The included studies on strain and lineage are summarized in S6 Table.
405 Differences are noted depending on the segment(s) of the viral genome analyzed, the
406 clustering algorithm used, and the reference isolate used as a 'type specimen' for
407 comparison.

408 Sub-lineages of the Eastern group were found in the 1997-1998 Kenya/Tanzania
409 RVF outbreak, as well as the 2000-2001 Saudi Arabia/Yemen outbreak [87, 88]. These
410 were most similar to the RVFV isolates from humans, animals and insects the Kenya
411 2006-2007 epidemic (when variants termed Kenya-1, Kenya-2, and Tanzania-1 co-
412 circulated) [87, 89]. Later 2008-2009 isolates from outbreaks in Comoros [90], Mayotte,
413 and Madagascar [91, 92] were also from the Eastern group. Although Eastern African
414 group isolates were recovered from Mauritania in 2010 [93] and Senegal in 2013 [94] in
415 West Africa, outbreaks in these countries in other years have identified a separate West
416 African lineage grouping of RVFV isolates [95, 96]. Grobbelaar and colleagues [97]
417 have used the sequence from the viral Gn surface peptide to compare 198 isolates
418 recovered between 1944-2010 from across Africa and the Arabian Peninsula, and have
419 defined 15 different lineages, which they have labeled A through O. South African
420 isolates in 2008 were grouped in the C lineage, related to the Kenya-1 lineage.
421 However, during 2009-2011, South African isolates were predominantly found in a new,
422 separate lineage H [98], while one isolate in Northern Cape Province was from lineage
423 K. Lineage K was later identified in a small South African outbreak in 2018 [99], and in
424 an RVFV-infected Chinese expatriate working in Angola in 2016 [100].

425 **Table 2. Rift Valley fever virus lineage determinations for isolates recovered in**
 426 **recent epidemics, based on cluster analysis of gene sequences for the viral Gn**
 427 **surface protein.** (Based on Grobbelaar, et al. 2011 [97])
 428

Grouping	Grobbelaar System	Year	Country	Species	Lineage Notes	Reference
East African	lineage C	2000-01	Saudi Arabia, Yemen	Human	Very similar to 1997-98 isolates/variants Kenya-1, Kenya-2, and Tanzania-1	[87, 88]
	lineage C	2006-07	Kenya	Humans, Livestock, Vectors		[87, 89]
	N/A	2007	Comoros	Humans	Similar to Kenya 2006-7	[90]
	lineage C		Madagascar			[91, 92]
West African			Mauritania, Senegal, Niger		Related to Kenya-1 lineage	[95, 96]
Southern African	lineage C	2008-09	South Africa			[97]
	lineage H	2009-11	South Africa			[101]
	lineage K	2009-11	South Africa			[101]
	lineage K	2018	South Africa			[99]
	lineage K	2016	Angola/China			[100]


429

430 **Human outbreak characteristics**

431 During human outbreaks, surveillance and reporting efforts varied greatly from
 432 location to location. We observed that among human outbreak reports, the calculated
 433 incidence rates of probable or confirmed human RVFV infections among local or
 434 regional residents varied between 0.01 and 91 per 100,000 population, with a median
 435 value of 2.5. Case fatality risks for these probable or confirmed cases varied from zero
 436 to 65% (median = 14.3%) in locations where more than one case was reported (n= 107
 437 locations from 41 publications, see S5 Table).

438 The cumulative human exposure to RVFV infection is also heterogeneous across
439 locations. In endemic areas, this cumulative exposure is usually estimated based on the
440 population prevalence of human anti-RVFV IgG seropositivity. Among the 25 well-
441 designed population-based serosurveys (scored as having low risk-of-bias) among our
442 included reports (n= 44), IgG seroprevalence during interepidemic periods ranged from
443 (0.15%) in Madagascar in 2014-2015 [40] to 22% in eastern Kenya in early 2006 [102]
444 and again in 2013-2014 [103], with an overall median intra-epidemic value of 5.2% (IQR
445 1.8% - 13%) seropositivity across all 25 surveys.

446
447




448

449 **Fig 5. Acute human RVF events per year during 1999-2021, by geographic regions**
450 **across Africa, the Indian Ocean, and the Arabian Peninsula**

451

452 Acute human RVF outbreaks were reported across Africa, the Arabian Peninsula, and
453 the Indian Ocean from 2000-2021 (Fig 5). The highest number of reported human RVF
454 events occurred in 2006-7, starting in East Africa, moving to Sudan (North Africa) and
455 then to the islands in the Indian Ocean during 2007-2008, as part of an evolving
456 epidemic and epizootic of the East African RVFV lineage. In East Africa, new RVFV
457 outbreaks have recurred annually since 2016, whereas no new human cases have been
458 reported in the Arabian Peninsula since 2001. RVF flared in southern Africa in multiple
459 episodes between 2008 and 2011 and West African countries Mauritania and/or
460 Senegal have reported cases across multiple years, 2003. 2010, 2012-3, 2015-6, and
461 again in 2020.

462



463

464 **Fig 6. Acute animal RVF events per year during 1999-2021, by geographic regions**
465 **across Africa, the Indian Ocean, and the Arabian Peninsula**
466

467 A larger number of acute animal RVF events (N = 273), compared to human events (N
468 = 132), was reported during the 1999-2021 period studied. The reported animal events
469 in southern Africa (N= 31) and in the Indian Ocean islands (N= 19) were concentrated
470 during the 2008-2011 period (Figs. 5 and 6). By contrast, animal events in West Africa
471 and East Africa were reported during most years of the targeted time interval
472 (cumulative N= 80 and N=118, respectively), with the highest yearly tally being 41
473 reported events in 2018 (Fig 6). No animal event was reported in the Arabian Peninsula
474 after 2010, while only a low number of events were reported in Central and North
475 African countries between 2002-2019 (cumulative N= 8 and N= 9, respectively; Fig. 6).

476 Of 28 papers that reported both human and livestock data, 17 contained
477 information on concurrent co-local RVF epidemic and epizootic activity. These reports
478 documented combined human/animal RVFV transmission events in Saudi Arabia [104,
479 105] and Yemen [106] in 2000-2001; in Egypt [107] and Mauritania [108] in 2003; in
480 Kenya [5, 89] and Tanzania [89, 109] in 2006-2007; in Mauritania in 2010 [93, 110] and
481 again in 2012 [111]; in Senegal in 2013-2014 [94]; in Niger [96] and in Uganda [112] in
482 2016; and in Kenya [113] , Mayotte [114], and South Africa [115] in 2018.


483 **Evidence of vector presence and competence for interepidemic RVFV**
484 **transmission.** In S7 Table we summarize 31 published studies from 1999-2021 that
485 tested insect vector species for RVFV infection potential. Our systematic review
486 identified 21 locations with RVFV-positive vectors, including mosquitos from *Aedes*,
487 *Culex*, *Anopheles*, and *Mansonia* spp. and from *Hyalomma* spp. ticks (Fig. 2). Notably,

488 in 6 out of 10 trapping surveys performed during interepidemic years in endemic zones,
489 live RVFV or RVFV RNA was detected in captured vector mosquitoes or ticks [116-121].
490 As the lifespan of mosquito vectors is relatively short, the presence of RVFV viral RNA
491 in these vectors likely represents sustained circulation in each of the given locations.

492 **Human risk of RVFV-related disease.** Among our included studies from the
493 systematic review, 84 reports assessed human risk factors for RVFV exposure. The
494 factors most commonly assessed were occupation (33 papers), gender (30), age (89),
495 contact with animals (38), travel (15), as well as proxies for mosquito exposure such as
496 work or residence in proximity to water sources (12), and personal behaviors related to
497 mosquito avoidance (29).

498 Quantitative assessment of the role of gender involved estimation of chances for
499 RVFV exposure by men and women in endemic settings. There were 31 studies that
500 reported RVFV exposure (cases or anti RVFV seropositivity) according to gender (Fig
501 7). There was moderate heterogeneity among these studies ($I^2 = 39\%$), and random
502 effects modeling estimation yielded a summary pooled OR estimate of 1.41 ($CI_{95\%}$ 1.24,
503 1.60, $p < 0.001$) for males vs. females in their exposure rates (Fig 7). This value, based
504 on studies from 1999-2021, remained very similar to that calculated by Nicholas and
505 colleagues [64] (OR = 1.36) in their meta-analysis of studies from 1984-2011.

Male:Female Odds Ratio for Human RVFV Infection



506


507 **Fig 7 Meta-analysis of the impact of human gender on odds of RVFV exposure in**
 508 **at-risk populations**

509

510 **Greater human risk associated with animal contact.** Eleven well-structured
 511 human surveys (having moderate to low risk of bias, i.e., LQAT scores ≥ 6) compared
 512 rates of RVFV exposure among local residents according to the extent of their daily
 513 contact with animals, particularly ruminant livestock. Heterogeneity was high among
 514 these studies ($I^2 = 68\%$). However, random effects meta-analysis, summarized in the
 515 Forest plot in Fig 8, yielded a summary OR estimate signifying a 46% increase in the
 516 odds of RVFV exposure among people with regular animal exposure (random effects
 517 model pooled OR = 1.46, $CI_{95\%} = 1.09, 1.94$, $p = 0.01$) in at risk populations. In separate

518 task analyses, S1-S3 Figures show Forest plots for summary estimates of associations
 519 between butchering, sheltering, and milking livestock activities and risk of RVFV
 520 exposure among at-risk populations. The estimates were: for butchering, OR = 3.7
 521 (CI_{95%} = 2.5, 5.4, p < 0.001, I² = 75%); for sheltering, OR = 3.4 (CI_{95%} = 2.1, 5.4, p <
 522 0.001, I² = 57%); and for milking, OR = 5.0 (CI_{95%} = 2.8, 8.8, p < 0.001, I² = 77%),
 523 indicating significantly higher risk with these exposures. Among these pooled studies,
 524 there was no evidence of publication bias (by funnel plot or by Eggar’s statistic). There
 525 were no yearly trends in exposure effects, nor did sensitivity analysis indicate evidence
 526 of any single dominant study for each exposure-related outcome.


Odds Ratio of RVFV Infection When Exposed to Animals



527

528 **Fig 8 Meta-analysis of the impact of animal exposure on odds of RVFV exposure**
 529 **in at-risk populations.**

Odds Ratio of RVFV Infection When Handling Abortus



530

531 **Fig 9 Meta-analysis of the impact of handling RVF-related animal abortions on**
 532 **odds of human RVFV exposure in at-risk populations**

533

534 Thirty-nine included studies assessed human RVFV-infection risk factors related

535 to different animal exposures and 17 of those studies linked animal exposures to acute

536 human RVFV infections (S8 Table). In meta-analyses performed according to specific

537 animal contact tasks, handling aborted material during an RVF outbreak had the

538 greatest pooled odds ratio of human infection (random effects model pooled OR = 3.65,

539 $CI_{95\%} = 2.32, 5.73, p < 0.001, I^2 = 73\%$).

540 Our survey also provided individual reports of an additional 21 significant animal

541 contact risk factors that had not been commonly assessed. In a study in Tanzania

542 during the 2006-2007 East Africa outbreak, 40% of 115 RVFV cases reported having

543 contact with animal products including meat and milk from sick animals, compared to

544 just 28% of the cases reporting having slaughtered an animal [122]. Specifically,

545 consumption of meat from sick animals was associated with a nearly four-fold increased
546 risk of RVF-associated death during the 2006-7 outbreak in Kenya [68].

547 **Occupational and socioeconomic factors associated with RVFV exposure.**

548 Our systematic review identified seven studies overall that found statistically significant
549 risks related to socioeconomic factors such as education level, ethnicity, and household
550 size. Briefly, the less wealthy and less educated were overrepresented among RVFV
551 exposed people (S9 Table).

552 Forty-five of the 506 papers assessed occupation as a human risk factor and 14
553 references found occupation to be a statistically significant factor (S10 Table). For
554 clarification, those who were classified as ‘herders’ may not necessarily live a pastoralist
555 lifestyle, so they have been given separate status. We found three studies that reported
556 high seroprevalence among “housewives”, which might be explained by their frequent
557 handling of raw meat and animal products for cooking.

558 **Risk Factors for RVF severity.** Out of the 135 included papers assessing
559 human RVFV exposure and disease, 12 presented data on human risk factors
560 associated with more severe RVF disease presentation (S8 Table). Persons with animal
561 contact were usually more likely to have had severe disease, [21, 123, 124]. In
562 outbreaks in Kenya [123, 124], specific animal contact activities such as handling or
563 consuming products from obviously sick animals (OR for more severe disease = 2.53,
564 $CI_{95\%} = 1.78, 3.61$, population attributable risk percentage [PAR%] = 19%) and touching
565 an aborted animal fetus (OR = 3.83, $95\% CI_{95\%} = 1.68, 9.07$, PAR% = 14) were strongly
566 linked to risk of severe rather than mild human RVF disease. Older age and death of a
567 family member were also linked to more severe human disease [123]. In Sudan, males

568 aged 15-29 years were overrepresented among patients who presented with severe
569 disease, as compared to females of the same age [125]. Environmental factors, such as
570 excess rainfall and muddy soil linked to emergence of mosquito blooms have also been
571 linked to severe human disease in both Sudan and Kenya [126, 127].

572 Severity of human RVF was associated with the presence of concomitant co-
573 infections. A fatal outcome in a travel related case was attributed to the presence of
574 concurrent hepatitis A virus infection [45]. Additionally, a study in South Africa during the
575 2010 RVFV outbreak indicated that existing HIV-positive infection status was associated
576 with risk of the encephalitic form of RVF disease [128], a finding similar to experience
577 among HIV-infected patients in Tanzania in 2007, where all patients with HIV-positive
578 status developed encephalitis, and of whom 75% died [122].

579 Four studies performed in three countries (Kenya, Sudan, Saudi Arabia),
580 examined the risk factors linked to death from RVF. In Kenya in 2007, consuming and
581 handling products from sick animals and village and district location were linked to risk
582 of death (OR = 3.67, CI_{95%} = 1.07, 12.64, PAR% = 47%) [124, 129]. In Saudi Arabia, a
583 retrospective analysis of the 2000-2001 outbreak showed that specific clinical signs
584 were independently linked to death. These included jaundice, bleeding, and neurologic
585 symptoms ($P < 0.0002$) [130]. One study demonstrated an increased level of RVFV
586 replication in fatal RVFV [131].

587 **Risk factors for animal RVFV outbreaks.** Because human risk of RVFV
588 exposure is closely associated with the local presence of infected livestock, we
589 reviewed factors related to animals' risk of RVFV infection.

590 *Herd Immunity Levels.* Our systematic review included results from 174 animal
591 studies, in which 144 tested domestic livestock and 26 tested wild animals for RVFV
592 exposure and/or acute infection. Of all livestock studies included, 32 were conducted
593 during an active epizootic, 10 were conducted just after an outbreak in the post-
594 epidemic phase, and 97 were conducted during interepidemic years. For wildlife
595 surveys, 5 were carried out during an active epizootic, 5 were done in the post-epidemic
596 phase, and 14 were performed during interepidemic periods. Of all animal risk factors,
597 sex and age were the most studied, and older animals and those that had lived through
598 outbreaks were more likely to have been exposed. A summary of livestock risk factors is
599 presented in S11 Table.

600 *Herd Level Risks.* For herd level risks, the observed effects of herd size has
601 varied across studies. A 2013-2014 study in a high risk area of Kenya showed that
602 medium sized herds of 50-100 animals had a significantly higher seroprevalence
603 compared to small herds (< 50 animal) or very large herds (>100 animals) [132], though
604 this did not account for the differences in animal rearing strategies dependent on herd
605 size. The statistical significance of herd size was lost when village was accounted for as
606 a random effect [74]. In Tunisia, the first assessment of serology in camels in 2017-
607 2018 showed that camels living in smaller herds intended for meat production had a
608 higher seroprevalence than those used for military purposes or tourism. Additionally,
609 this study found that camels that had contact with ruminants had significantly higher
610 rates of RVFV exposure [80].

611 The differing levels of RVFV susceptibility across livestock species (S11 table)
612 further complicates the herd immunity threshold related to animal-to-human RVFV

613 spillover. Additionally, livestock had variable contact with other livestock from
614 neighboring herds and regions. An extensive social contact analysis from the 2008-
615 2009 Madagascar outbreak showed that bartering practices, in which cattle can have
616 multiple contacts within a village, was a significant seroconversion risk factor [133].
617 Such bartering practice can support for inter-village RVFV circulation, whereas formal
618 trade networks or cross-border smuggling were more likely to be responsible for trans-
619 national spread [134, 135].

620 *Individual Animal Risks.* For individual-level animal risk, studies examining cattle
621 had the most significant findings. Abortion was the most recognized clinical sign
622 associated with RVFV infection and recent abortion was significantly associated with
623 RVFV exposure [136]. This experience was the first to identify the 2018 RVFV
624 outbreaks in Kenya when farmer-reported surveillance was implemented [126]. None of
625 the included studies found an association between underlying animal body condition
626 and RVF risk.

627 **Wild animals' role in RVFV transmission.** RVFV has been found in a variety of
628 wild mammals [48]. Wild ruminants, especially buffalo, have been found to have
629 significant herd seroprevalence during inter-epidemic period in endemic areas [46, 137,
630 138]. For species-specific risk factors, interspecific network centrality, home range and
631 reproductive life-history traits were associated with RVFV occurrence. S12 Table
632 summarizes the wild animal seropositivity and acute infections identified in our literature
633 review.

634 **Animal Vaccination.** Among the included papers in this review, we identified 17
635 studies in six countries that included vaccinated animals. Countries that had vaccinated


636 cattle, sheep, or goats for RVFV were Kenya, Tanzania, South Africa, Egypt, and Saudi
637 Arabia [5, 139-143]. In Egypt, between 2013 and 2015, seroprevalence of anti-RVFV
638 was 14.9% among immunized cattle, compared to 7.9% among unimmunized cattle
639 [144]. Although livestock are required to be vaccinated before they are exported to
640 Saudi Arabia, a study at a livestock quarantine facility in Djibouti found an anti-RVFV
641 IgM-positive seroprevalence of 1.2% in sheep and goats (small ruminants grouped as
642 'shoats') and 0.3% in cattle [139, 145]. A 2009 study in Mecca, Saudi Arabia found
643 55.8% anti-RVFV IgG in ostensibly vaccinated sheep, but still found a 2.6% rate of IgM
644 positivity, indicating possible ongoing circulation (despite herd vaccine status) or recent
645 vaccination[146].

646 **Additional considerations for RVF risks.** The range of RVFV is expanding,
647 and it appears to travel well [39, 147, 148]. In endemic countries, internal travel to or
648 from outbreak epicenters is typically included in suspect case definitions. A recent
649 review by Grossi-Soyster and LaBeaud [149] has highlighted the risk of RVFV
650 transmission to travelers, and although most travelers will not have direct contact with
651 livestock, their mosquito exposure behavior needs to be assessed.

652 **Reported surveillance methods** in animal, humans or vectors are summarized
653 in S13 Table. Our review revealed 52 papers specifically reporting on RVFV
654 surveillance. Their methods are not uniformly implemented, but include: i) leveraged
655 RVFV testing of samples taken during surveillance for other diseases such as malaria,
656 dengue, HIV, and Lassa fever [38, 150-152]; ii) the use of sentinel livestock herds in
657 high-risk areas; iii) increased case surveillance based on monitoring of weather-related
658 early warning signs; and iv) international collaborations with neighboring regions to

659 conduct surveillance. These surveillance systems do not necessarily operate in parallel,
660 but instead may overlap and may only be implemented at times of perceived increased
661 risk.

662 Fig 10 depicts the different types of early warning and surveillance systems and
663 their relative certainty. S13 table further summarizes available information from open-
664 source platforms on the early warning and surveillance systems used for RVFV
665 transmission during 1999-2021.



666
667 **Fig 10 Progressive scale of surveillance that can be used to indicate an impending RVFV disease**
668 **outbreak**

669 Republished with permission of The National Academies Press, from Under the Weather:
670 Climate, Ecosystems, and Infectious Disease (2001), Chapter 7: Towards the Development of
671 Disease Early Warning Systems. P. 87; permission conveyed through Copyright Clearance
672 Center, Inc. under license ID #1142222

673
674 **RVFV Diagnostics.** When implementing surveillance for detecting RVFV

675 transmission, one major constraint is the limited availability of accurate diagnostics in
676 places where RVF disease occurs. For both human and animals, reliance on a clinical

677 presentation to prioritize RVFV testing is complicated by the significant clinical
 678 diagnostic overlap with other febrile infection syndromes.

679 Although detection of circulating RVFV RNA by RT-PCR can be a definitive
 680 diagnosis of active infection, because the human and livestock viremic period is typically
 681 only 4-6 days (up to 14 days if hemorrhagic human disease), serologic testing is more
 682 extensively used to investigate the epidemiology of recent and past infection. We
 683 extracted data from 207 included review reports on the type of assays recently
 684 employed for diagnosis of acute RVF. No studies tested livestock and wild animals
 685 together for acute infection. The assays used to detect acute RVFV infections are
 686 summarized in Table 3.

687

688 **Table 3: Summary of acute diagnostic assays employed in included studies, by**
 689 **species**

Number of Included Studies that Used the Following Methods for Detection of Acute RVFV Infection												
Species	IgM	IgM, direct ¹	IgM, PCR	IgM, PCR, direct ¹	IgM, PCR IgG SC ²	IgM, IgG SC ²	PCR IgG SC ²	Direct ¹ only	PCR only	PCR, direct ¹	IgG SC ² only	Total
Livestock	26	0	4	0	1	3	2	0	5	0	3	44
Humans	21	2	23	4	2	0	0	2	9	1	0	64
Humans, livestock	1	1	5	3	1	0	0	0	1	0	0	12
Humans, livestock, wildlife	0	0	0	1	0	0	0	0	0	0	0	2
Wildlife	0	0	1	0	0	0	0	1	0	1	1	4
Method Total	48	3	33	8	4	3		3	15	2	4	

690 ¹Direct: Direct detection methods include immunofluorescence assay, cell culture (virus
691 isolation), electron microscopy, and immunohistochemistry

692 ²SC: IgG Seroconversion of IgG (positive IgG during the study period AND a previously
693 documented negative status from the same individual)

694

695

696

697 **DISCUSSION**

698 During RVF epidemics, assessment of incidence, prevalence, and associated
699 risk factors for infection are often based on case series of suspected patients, rather
700 than well-designed, population-based surveys that enumerate laboratory-confirmed
701 cases vs. non-cases. Epidemic and epizootic outbreak surveys are further hampered by
702 limited access to the affected rural communities, which are often experiencing severe
703 flooding caused by excessive rainfall, and very limited access to diagnostic testing. In
704 addition, survey incidence/prevalence calculations may be imprecise because of lack of
705 accurate census information. As a result of these factors and the irregular frequency of
706 disease outbreaks, the epidemiology of RVFV transmission and the risk factors for
707 RVFV-related human disease are not well defined. In some endemic areas, post-
708 epidemic serosurveys have shown high community exposure to RVFV [68, 103, 151-
709 156], even though symptomatic RVF had been only rarely reported by local health care
710 services. Based on our consolidated picture of recent RVFV epidemiology and the
711 knowledge gaps we have identified, future operational research and clinical trial design
712 should consider the factors discussed below, with the understanding that currently
713 available data have some significant limitations in accurately defining human risk for
714 RVF.

715 Our review indicated that during the last two decades, new patterns of RVF
716 epidemiology have emerged. The virus continues to expand its range across Africa

717 countries and into new regions within endemic countries [58, 157]. It should be noted
718 that among studies that were technically excluded from our review, there were several
719 completely negative serosurveys of animals performed in Spain [51], the Canary Islands
720 [52], Mauritius [158], Zanzibar [159], South Korea [54], and Poland [53]. Expansion of
721 RVFV transmission has been aided by livestock movement [34, 160-163] and the
722 increasing frequency of extreme weather events involving heavy rainfall and flooding
723 [59]. The discovery of vertical transmission within insect vector species other than
724 floodwater *Aedes* spp. mosquitoes [164] indicates the existence of multiple pathways for
725 local RVFV persistence in different ecosystems during time periods that are in between
726 recognized outbreaks. An additional non-vector route of RVFV transmission to humans,
727 i.e., maternal-fetal transmission, has also been identified recently [165-167], and it has
728 been established that RVFV can be an abortifacient in humans [168]. Thus, treating
729 RVF as a concern only during large scale outbreaks in known hotspots fails to capture
730 the full burden of disease and its underlying transmission, and fails to detect new areas
731 of emergence.

732 The limited understanding of transmission persistence during interepidemic
733 periods is a major gap affecting our ability to control continued expansion of RVFV, both
734 within and between countries. Prospective studies during interepidemic periods are
735 needed to provide a deeper understanding of how RVFV survives then subsequently
736 thrives in an endemic area. Study findings could then suggest how mitigation efforts,
737 such as vaccination of high-risk humans, can be implemented even before existing
738 surveillance systems detect an outbreak.

739 **Gap 1: Defining the likely interval between significant RVF outbreaks is**
740 **challenging**, because without active case finding, passive detection is an imperfect
741 trailing indicator of transmission, as it requires a large enough case number of RVF
742 clinical syndromes (e.g., abortions in livestock) to identify events. Over the last two
743 decades, increased availability and sensitivity of RVFV diagnostic assays, including
744 genotyping, have contributed to increased recognition of viral transmission. However,
745 without baseline interepidemic surveys in both high and low risk areas it is not possible
746 to determine whether RVF outbreak waves are due to persistence or to re-introduction
747 of RVFV transmission. As the outbreak intervals for RVFV remain undefined, the lack of
748 studies during interepidemic periods limit our ability to understand viral maintenance
749 and make it difficult to qualify endemicity in support of mitigation efforts such as
750 vaccination. More useful data would include concomitant active surveillance of vectors,
751 livestock, and humans, and information on rainfall, temperature, mosquito larval
752 sources, and the frequency of risk-related human behaviors. Because RVF livestock
753 outbreaks are up to five times more likely to occur where outbreaks have previously
754 occurred, and human outbreaks are more likely to occur in the same locations as
755 livestock outbreaks [5, 169], areas with prior RVFV transmission shown in Figs. 3 and 4
756 would be best locations to characterize interepidemic transmission.

757 Kenya, South Africa, Madagascar, and Mauritania have had recurrent human
758 and domestic animal RVF outbreaks in the last two decades and are thus most likely to
759 experience additional outbreaks in the near future. Notably, areas with recurrent
760 outbreaks tend to have more robust surveillance which may account for the higher
761 frequency of RVF detection in those locations (i.e., ascertainment bias). Based on

762 findings identified in this systematic review, RVF can be more likely in a given location,
763 compared to a similar nearby location due to many factors, including the total number of
764 susceptible hosts (influenced by herd immunity), the presence of wildlife reservoirs
765 [170], the water retention properties of the soil and rainfall patterns [62], local cultural
766 practices that may increase (consumption of blood) or decrease risk (refusing to eat
767 meat from dead animals) [171], and mitigation efforts that persist between outbreaks.
768 As these factors can be confounded, an in-depth understanding of RVFV epidemiology
769 is needed to design investigations so that resources for operational research can be
770 maximized.

771 **Gap 2: The unpredictability of livestock herd immunity** Current prevention
772 and readiness efforts for RVFV outbreaks rely mostly on early warning prediction and a
773 rapid livestock vaccination response, both of which occur with variable reliability.
774 Recovery from infection and vaccination with live-attenuated vaccines are thought to
775 result in lifelong neutralizing antibodies in livestock [172] and indeed, if enough livestock
776 could be vaccinated for RVFV, then human spillover would be unlikely [173]. However,
777 livestock within and between herds have a rapid turnover rate as animals are
778 slaughtered and sold, or arrive naïve into the herd from new births or purchases.
779 Additionally, livestock in RVFV endemic countries often live in close proximity to wild
780 ruminant species that also acquire many naïve animals each breeding season. The
781 logistics and current intermittent nature of domestic livestock vaccination campaigns, in
782 the face of unknown baseline herd immunity levels, makes full reliance on reactive
783 livestock vaccination a risky approach to RVFV public health control.

784 Most livestock animal studies have focused on cattle, sheep, and goat
785 seroprevalence. Although some surveys have used power analysis to determine how
786 many animals to sample from each species, many surveys have still opted for
787 convenience sampling, focusing either on sheep and goats, which are easier to handle,
788 or on just cattle alone. The interpretation of such livestock prevalence surveys should
789 be viewed with caution. Animal age is also likely to influence the results-- cattle and
790 dairy animals tend to live longer than sheep or goats, so it can appear that their
791 cumulative burden of exposure is higher. However, evidence of infection among
792 younger animals does provide evidence for recent RVFV transmission activity, and
793 increased seroprevalence between years can indicate an unrecognized outbreak. When
794 multiple species are surveyed, rates should be calculated based on animal-years at risk
795 and better attempts should be made to age animals based on their dentition. Factors
796 that confound RVFV exposure risk should be captured, such as the wealth and
797 knowledge of the farmer [113], area livestock density, and location-specific climate
798 factors. We suggest factors such as nearby temporary and permanent water bodies,
799 land use, mobility at peak mosquito biting times, housing conditions, and rearing
800 strategy be combined with climate data to better discern spatial and temporal high-risk
801 periods for livestock. This will be important in defining optimal locations for human
802 vaccination trials.

803 As the previous systematic review by Clark, et al. [67] has highlighted, and as we
804 found in our review, there are few studies that assess both human and animals from the
805 same site at the same time. The high-risk periods for livestock and humans may not
806 necessarily overlap, as livestock infections are undoubtedly driven by rainfall and

807 mosquito blooms, but human outbreaks can also expand with increased slaughtering of
808 sick animals and the increased presence of secondary mosquito vectors.

809 It is understood that livestock viral amplification is an important predecessor of
810 human outbreaks. The greater number of acute animal events (N=273), compared to
811 human events (N=132) identified in this review could be due to our increasing ability to
812 detect smaller animal outbreaks or could represent our inability to reliably detect acute
813 human cases associated with smaller animal outbreaks [174, 175]. After animal
814 outbreaks are established, we recommend broad-based human outbreak investigations
815 that include all community members, not just the high-risk individuals, i.e., all individuals
816 who may have had contact with animal products from the affected herd, as well as
817 those who do not own livestock but reside in areas within vector flight range.

818 **Gap 3: Differences in seasonality across endemic/enzootic locations.** As
819 climate change modifies seasonal weather patterns, differences in outbreak incidence
820 are becoming more prominent among at-risk locations, but these changes may make
821 epidemics harder to predict. Eighty-nine (31%) of our included studies specifically
822 mention flooding at the outbreak site. A defined “rainy season” and “dry season” in
823 tropical locations can guide risk assessment, but it is not just rain that makes an
824 outbreak more likely. Congregation of many susceptible hosts and large volume
825 slaughtering of animals (for example, as part of religious or community festivals [146,
826 176, 177]), an abundance of mosquito breeding containers (for example, in plastic
827 trash) [178], large-scale animal movement [179], and low baseline herd immunity will
828 increase the chance of RVFV outbreaks. Recent data-driven modeling efforts by
829 Hardcastle and colleagues [58], incorporating environmental and human and animal

830 census data at the district level, predict that outbreaks in southern and eastern Africa
831 are most likely to occur in December through July, whereas risk in the Sahelian zone
832 will be higher in September through November [180]. Even within countries, seasonal
833 rainfall can vary widely. For example, in western Kenya, August typically has above
834 average rainfall while the remainder of the country remains dry [181]. Real-time regional
835 level weather information must be considered to obtain adaptive implementation of
836 mitigation efforts.

837 Pastoralist herds tend to have higher RVFV exposure, and this is influenced by
838 the types of ecozones where the herds circulate. Pastoralists follow water and pasture
839 availability as they become available in a seasonal cycle, which may involve movement
840 through high-risk zones. As animal protein demand increases, mostly in urban centers,
841 more livestock will be passing through areas that have previously experienced RVF
842 cases, and in the presence of competent mosquito vectors. Recent infections are more
843 common in nomadic herds compared to agro-pastoralist herds [182] and in herds with
844 longer distance to travel to their night pens or to the nearest permanent water [82].
845 Modeling of data from Senegal suggested that nomadic herd movements are sufficient
846 to account for endemic circulation of RVFV, although the co-existence of *Aedes vertical*
847 transmission cannot be ruled out [183].

848 In addition to climate, the variety of suitable hosts present in those areas will also
849 vary from location to location. All potential wildlife reservoir species should be
850 considered when comparing incidences between two geographically distinct areas
851 because wild animals' behaviors and range is intimately tied to topography and
852 resource availability. In Botswana, wildlife hunters' seroprevalence was 27% compared

853 to a 3% community level exposure [35], showing that wildlife exposure may contribute
854 directly to human burden independent of domestic livestock presence. This is further
855 illustrated by human case exposure in Angola without documented livestock exposure
856 [100]. As RVFV can adapt to new ecological niches and utilize a wide variety of
857 mammals to amplify itself, including common white-tail deer [184, 185], we caution not
858 to make the assumption that wild animals' role in RVFV transmission will be similar
859 between locations. All suitable wild animals, particularly wild ungulates, should in
860 included in calculations of regional herd immunity and their interface with humans
861 should be considered as a likely risk factor.

862 **Gap 4: Data challenges related to bias based on limited study designs and**
863 **inconsistent reporting.** A systematic review by Bron and colleagues [186] has
864 summarized the patchwork of data collected on RVFV epidemiology over the last
865 century, and has highlighted the lack of standardized reporting as the major challenge in
866 comparing data between locations. In our current systematic review, which focused
867 solely on studies from the last two decades, we confirm that uneven reporting remains a
868 significant problem. Improving study designs and sampling frameworks for RVFV is
869 challenging, in part due to the lack of funding opportunities during interepidemic periods.
870 In outbreak reports, uncertain levels of ascertainment bias and possible diagnostic
871 misclassification, mean that case finding and resulting case counts have unclear
872 accuracy. 'Population at risk' numbers used in incidence and prevalence calculations
873 are often chosen based on outdated census data without true understanding of who is
874 at risk within a community. With many smaller, low-budget, short-term studies (rather
875 than large collaborative long-term efforts) the focus turns to identifying enough cases for

876 a meaningful statistical analysis, which means that some studies will test only high-risk
877 individuals working with animals. This likely excludes vulnerable populations who have
878 not yet been identified as being at high-risk.

879 Hospital-based surveys for hemorrhagic fever surveillance are an attractive tool
880 because they do not require household field visits and blood samples are typically more
881 available for testing [38, 40, 150-152, 187, 188]. Such sero-surveillance can be
882 compared from year to year to gain retrospective insight on when transmission has
883 occurred. However, as with most hospital-based studies, these efforts do not represent
884 the population at large, so they likely underestimate true incidence and overestimate the
885 percentage of cases with severe disease.

886 **Gap 5: Delineating human risk factors.** This meta-analysis of human risk
887 factors across multiple 1999-2021 studies confirm the increased RVFV infection risk
888 associated with male gender, general livestock care, contact with animal abortus,
889 butchering animals, and milking risks, identified in previous reviews and meta-analysis
890 [64, 189]. Not all of the studies in this systematic review were population-based, thus
891 the variable reporting of associations having ‘statistical significance’ may be attributed to
892 differences in study design, low sample size with lack of statistical power, and/or choice
893 of target populations.

894 In most places where RVFV outbreaks occur, lack of health care infrastructure
895 impedes detailed description of human disease signs and performance of laboratory
896 studies (including assessment of viral load and immunologic responses to infection),
897 which might be predictive of severe disease or death. It is possible that other health
898 comorbidities, such as concurrent HIV or hepatitis, can influence the presentation of

899 RVFV disease, but these associations have not yet been widely studied. Further
900 descriptions of the natural history of clinical and laboratory findings in human RVF are
901 needed, and efforts should be made to fully assess the relative risks from direct (non-
902 vector) animal exposures vs. mosquito vector-borne exposure. Frontline healthcare
903 workers need to recognize when testing for RVFV infection is appropriate, based on
904 patients' significant risk factors, and they should communicate frequently with local
905 veterinary colleagues to identify high-risk transmission periods.

906 Most risk factor analyses rely on participant recall, risking recall bias, and it has
907 been difficult to discriminate the risk of living in the presence of susceptible livestock
908 from risk due to direct participation in husbandry activities or from risk due to local
909 mosquito exposure (including variably zoophilic and anthropophilic mosquito species).
910 Aside from animal rearing activities, the association of human risk with consumption of
911 infected animal products is concerning, as this is practiced by a majority of human
912 populations and the true infectivity by consumption is still not well understood. For
913 example, consumption of raw milk is a now well recognized as an RVFV exposure risk
914 factor [64, 189], but no previous studies have isolated RVFV from milk during outbreaks.
915 Ongoing studies in Kenya (Gerken et al, unpublished), are conducting risk assessments
916 in urban areas to distinguish consumption risk factors versus risk from livestock rearing
917 activities common to rural areas.

918 RVF has been perceived as a disease of poverty, but this is likely due to its
919 greater incidence recognized in rural areas. It is not known whether RVFV has an urban
920 transmission cycle, and so far, the risk of RVF related to socioeconomic status (aside
921 from having a pastoralist lifestyle) is poorly defined. Choice of occupation is intimately

922 connected to socioeconomic status and this systematic review confirmed that the
923 highest-risk occupations are associated with livestock exposure. Even within
924 occupational categories, differences in assigned tasks can carry differential risks [190].
925 We combined common terminology for the same profession, for example,
926 slaughterhouse and abattoir workers for our analysis; however, more specific factors
927 such as size of the slaughterhouse, species slaughtered, and available personal
928 protective equipment (PPE) are likely strong confounding factors.

929

930 **Gap 6: Need for consistent naming of RVFV lineages and strains.** A possible
931 explanation for variation in RVF attack rates and disease severity, noted between
932 locations and among different hosts, could be differences in RVFV strain virulence.
933 Laboratory studies suggest some strain-specific differences in mortality in experimental
934 animals [191]. However, the variability observed during natural outbreaks is likely due to
935 site-related diagnostic misclassification of RVFV infection with erratic failure to detect
936 milder cases of disease. Our systematic review aimed to capture strain- and lineage-
937 specific effects; however, a meaningful analysis was obscured by inconsistent naming
938 of lineages due to differences in the genetic sequences chosen to be studied and
939 different approaches to sequence homology analysis. International harmonization of
940 lineage identity and nomenclature will help to determine differential effects, if any, of
941 individual RVFV lineages and strains. As with SARS-CoV2 variants, a naming scheme
942 that does not rely on location may help to alleviate some of the disincentive and stigma
943 for national governments to report acute cases and identify sequences of circulating
944 genomes to identify sources of local introduction.

945 **Gap 7: Need for consistent RVFV testing frameworks.** As highlighted earlier,
946 identification of RVFV outbreaks and determination of the endemic state of a country
947 require consideration of the efficacy of surveillance efforts in place. Well organized and
948 implemented surveillance systems provide the basis for understanding the epidemiology
949 of RVFV and provide an opportunity to provide early warning and an opportunity to fill
950 the gaps in current knowledge.

951 As RVFV diagnostics become more widely available, physicians in
952 hyperendemic regions will be able to consider co-infection with RVFV in their differential
953 diagnoses, especially for pregnant mothers who are at risk for abortion [168].
954 Additionally, if hospitals are aware of current RVFV circulation in livestock, they can go
955 on high-alert and intensify their screening of patients for RVF. However, the lack of
956 specific medical therapeutics may dissuade clinicians from testing for RVFV and favor
957 testing for more treatable conditions, notably malaria. As the recent experience with
958 Ebola virus in West Africa has taught, compassionate care must be the cornerstone of
959 outbreak response in order for the at-risk population to buy into control measures.
960 Public health messaging that fuels despair results in massive underreporting,
961 particularly if outbreaks become political [192].

962 There are concerted efforts to create a pan-viral hemorrhagic fever diagnostic
963 assay. The Uganda Virus Research Institute (UVRI) in Entebbe has been implementing
964 laboratory-based surveillance for viral hemorrhagic fevers (VHF) in Uganda since 2010,
965 which includes testing for RVFV [193]. While this may help differentiate RVFV from
966 other concerning viruses, we caution about the grouping of RVFV with other
967 hemorrhagic fevers for surveillance purposes, as RVF-related hemorrhage in humans is

968 the rarest clinical manifestation, and the risk factors for other forms of RVFV-related
969 disease are different.

970 Development of robust RVFV surveillance systems is complex, because both
971 animals and humans display variably detectable disease outcomes when they become
972 infected. Currently, most RVFV surveillance systems are engaged only in response to
973 climate early warning systems and are focused on periods with high-risk for large scale
974 outbreaks. We found that recent re-structuring of the FAO Global Animal Disease
975 Information System (EMPRESi) has provided an open-source, easy to navigate platform
976 for tracking reports of RVFV cases in member countries. Since 2004, the system has
977 recorded 1,186 animal cases of RVFV, of which 1,175 were confirmed. This reporting
978 system relies on mandatory reporting of acute cases by national authorities, the OIE,
979 WHO, FAO field officers, and published reports such as those included in this review.
980 However, this database excludes longitudinal seroconversions, and therefore, excludes
981 evidence of sub-clinical transmission during interepidemic periods. Modeling
982 approaches using only these data should consider this key missing piece in their
983 assumptions. Although RVFV is a reportable disease in many of the affected countries,
984 a system that relies on passive reporting is likely to miss areas of new emergence when
985 viral activity is below the threshold to detect excess numbers of patients with the more
986 obvious clinical signs of RVF. It should be noted that the partnership of a strong national
987 veterinary service with close ties to a fully equipped national laboratory is crucial to any
988 successful surveillance effort. If farmer-based cellphone reporting is to be successful at
989 identifying RVF cases, farmers need to be sensitized to the greater goals of the system
990 and incentivized to report. Overall, the ideal surveillance system for RVFV would utilize

991 aspects of each of the discussed surveillance types (Fig 10), focusing on sentinels and
992 enhanced active case finding, including during interepidemic periods, and take into
993 account regional differences in animal and human health systems. Since RVFV is a
994 vector-transmitted disease, and a large proportion of the world has the potential for
995 RVFV emergence, the management of RVFV surveillance efforts should be regionally
996 collaborated and all RVFV-naive countries with large numbers of livestock should take
997 into account past lessons about recent new geographic introduction as they prepare
998 prevention and mitigation efforts for themselves [194-199].

999 Post-epidemic performance analyses have found that the lead time given by
1000 early warning systems may not be sufficiently long to prepare and vaccinate enough
1001 livestock to contain an outbreak. Just as reliance on a passive surveillance system for
1002 RVFV is likely to not be enough to detect outbreaks, sole reliance on a remotely sensed
1003 early warning systems (EWS) should also be avoided. One major limitation of climatic
1004 EWS is that they do not account for the effect of herd immunity, either through natural
1005 infection or prior livestock vaccination. Livestock seroprevalence as high as 60% have
1006 been captured in high risk areas [200] and up to 38% in areas that are not typically
1007 classified as high risk, such as Chad [201]. The lack of outbreak detection, despite
1008 seemingly high-risk weather conditions, can be explained both by the effect of herd
1009 immunity and limitations of existing surveillance systems. With this current level of
1010 performance, at-risk countries should not rely solely on early warning systems and
1011 instead use them as part of integrated decision support tools, similar to those developed
1012 for the greater Horn of Africa [202]. As RVFV outbreaks have often had an insidious

1013 onset, we recommend active case finding in high-risk areas in response to any of the
1014 previously mentioned early warning signals.

1015 **Gap 8: Evolving better approaches to diagnostics.** Because arboviral
1016 infections such as RVF often result in self-limited febrile syndromes with non-specific
1017 signs and symptoms, isolated cases of infection are frequently misdiagnosed as malaria
1018 in sub-Saharan Africa. This highlights the critical need for affordable and accurate point-
1019 of-care diagnostics for RVFV [203-206]. In the majority of recent transmission surveys,
1020 anti-RVFV IgM serology was used alone to define recent infection, and more humans
1021 than animals were found to be positive. As commercial IgM ELISA tests are now more
1022 widely available for livestock, this gap likely represents a lack of available resources,
1023 either financial or logistical, for testing livestock for recent infection. For suspect acute
1024 cases, IgM allows a wider window of detection than discovery of circulating virus or viral
1025 RNA [207].

1026 Among the 95 studies that reported human serology, the methods for human
1027 anti-RVFV antibody detection exhibited significant variability, with most studies relying
1028 on tertiary reference laboratories for final diagnosis. Future efforts should focus on
1029 increasing the number and capacity of local laboratories so that the burden of shipping
1030 time and costs can be alleviated. The Covid-19 pandemic response has led to
1031 expansion of molecular diagnostic capacity in many regions. In the aftermath of the
1032 pandemic, these important logistical and laboratory resources should be leveraged to
1033 include other viral diseases such as RVF.

1034 Serology serves as the basic approach for investigating individual and
1035 community level risk factors as it can monitor changes in prevalence over time. Both

1036 enzyme-linked immunosorbent assays (ELISA) and viral neutralization tests (VNT) have
1037 advantages and disadvantages. Identifying IgG-positive livestock by ELISA has often
1038 been the first step in recognizing new areas of emergence [80, 208]. However, follow up
1039 VNT should be used to confirm positive ELISA results in new locations, especially if the
1040 seroprevalence is low (less than 1-2%) when misclassification due to false-positive tests
1041 is of concern.

1042 **Gap 9: The need for One Health approaches for RVFV detection and**
1043 **control.** Expanding RVFV surveys to include human community populations at-large
1044 will identify risk associated with socioeconomic standing, while simultaneously detecting
1045 patients with incident infections but without presently known risk factors. To fully
1046 understand the ecology of local transmission such broad-based human studies need to
1047 be conducted concurrently with robust animal surveys. Recent reviews and policy
1048 papers in the human and animal health RVFV literature call for a greater emphasis on a
1049 One Health management approach, both in research and control efforts [127, 209, 210].
1050 A better understanding of viral transmission to all species during interepidemic periods,
1051 with an improvement of diagnostic sampling frameworks, are within reach in the next
1052 decade. Reaching an understanding of the herd immunity threshold for outbreak
1053 initiation, the variability in case fatality risks, the contributions of vectors to both
1054 asymptomatic and symptomatic human and animal infections, and the most influential
1055 transmission pathways will take a collaborative effort among multiple disciplines and
1056 public health sectors. The gaps presented here are based on a collated estimates of
1057 recent RVFV transmission. The available case counts and serosurveys in this

1058 systematic review contribute to a body of evidence that can guide the way forward to
1059 clinical testing of novel preventive and curative interventions.

1060 **Summary.** RVFV continues to transmit across Africa and nearby Indian Ocean
1061 islands at a high rate, but at an irregular frequency. As previously noted, because of its
1062 typical mosquito-borne re-emergent transmission, RVFV outbreaks often follow periods
1063 of excess rainfall and local flooding, particularly in semi-arid regions. During the 1999-
1064 2021 period studied in this review, animal and human outbreaks of RVF occurred at an
1065 average rate of 5-6 events per year across the region. The range of transmission has
1066 expanded, with human cases documented for the first time in Saudi Arabia, Yemen,
1067 Comoros, Mayotte, Burundi, Niger, and Mali, and with re-emergence in Uganda after
1068 multiple decades of no activity. Reported human RVF events were most common in
1069 Mauritania, Kenya, Sudan, Madagascar, and South Africa, and each of these countries
1070 experienced multiple epidemics since 1999. In districts or counties where human cases
1071 were reported, the median attack rate was 2.6 per 100,000 (range 0.1 to 91), and
1072 median case fatality was 14.1% of severe cases, highlighting the significant population
1073 health burden of RVF.

1074 Experience with veterinary vaccines indicates that pre-event vaccination can
1075 mitigate the spread of RVFV infection. Now that human vaccines are under
1076 development, and their clinical testing and implementation should be guided by
1077 particular focus on the high-risk subgroups (based on location and exposures) identified
1078 in this review. Effective vaccine trials will depend on achieving accurate outbreak
1079 predictions combined with efficient animal and human case surveillance systems.

1080

1081 **Acknowledgments**

1082 The authors would like to acknowledge the very helpful guidance provided by members
1083 of the CEPI literature review advisory group: Dr. Brian Bird, Dr. Baptiste Dungu, Roice
1084 Fulton, Dr. Jeroen Kortekaas, Dr. Paul Oloo, Dr. Janusz Paweska, Dr. Melinda Rostal,
1085 and Dr. George Warimwe.

1086 We also acknowledge the assistance of RVFV research collaborators who provided
1087 their unpublished survey data for inclusion in this study: Garja S. Suner, Pius S. Ekong,
1088 Elysse N. Grossi-Soyster, Mabel K. Aworh, Yiltawe S. Wungak, Nanven A. Maurice,
1089 Michael J. Ekong, and Bonto Faburay.

1090

1091 **Figure legends**

1092 **Fig 1. PRISMA systematic review flow diagram of data collection and evaluation**
1093 Online searches for publications and data registers (left side flow) were supplemented
1094 by governmental outbreak reports, non-indexed citations found in local archives, and
1095 citations found within the reference lists of the papers that were reviewed (right side
1096 flow). Data from one unpublished study were also included for evaluation.

1097

1098 **Fig 2. Regional map of countries exposed to RVFV infection based on findings of**
1099 **studies included in the systematic review.** Countries were categorized as to whether
1100 there was evidence of human, animal, or insect RVFV infection during the 1999-2021
1101 era.

1102

1103 **Fig 3. Sub-national administrative regions experiencing acute human cases of**
1104 **RVF during the years 1999-2021** Locations are shaded according to whether they
1105 experienced outbreaks before or after 2011, or if they had outbreaks during both
1106 periods of time.

1107

1108 **Fig 4. Sub-national administrative regions experiencing acute animal cases of**
1109 **RVF during the years 1999-2021** Locations are shaded according to whether they
1110 experienced outbreaks before or after 2011, or during both periods of time.

1111

1112 **Fig 5. Acute human RVF events per year during 1999-2021, by geographic regions**
1113 **across Africa, the Indian Ocean, and the Arabian Peninsula**

1114

1115 **Fig 6. Acute animal RVF events per year during 1999-2021, by geographic regions**
1116 **across Africa, the Indian Ocean, and the Arabian Peninsula**

1117
1118 **Fig 7 Meta-analysis of the impact of human gender on odds of RVFV exposure in**
1119 **at-risk populations**

1120
1121 **Fig 8 Meta-analysis of the impact of animal exposure on odds of RVFV exposure**
1122 **in at-risk populations.**

1123
1124 **Fig 9 Meta-analysis of the impact of handling RVF-related animal abortions on**
1125 **odds of human RVFV exposure in at-risk populations**

1126
1127 **Fig 10 Progressive scale of surveillance that can used to indicate an impending**
1128 **RVFV disease outbreak.** Republished with permission of The National Academies
1129 Press, from Under the Weather: Climate, Ecosystems, and Infectious Disease (2001),
1130 Chapter 7: Towards the Development of Disease Early Warning Systems. P. 87;
1131 permission conveyed through Copyright Clearance Center, Inc. under license ID
1132 #1142222

1133

1134

1135 **References**

- 1136 1. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health
1137 problems. Arch Med Res. 2002;33(4):330-342. Epub 2002/09/18. doi: 10.1016/s0188-
1138 4409(02)00378-8.
- 1139
1140 2. CDC. Rift Valley Fever. Viral Hemorrhagic Fevers: Fact Sheets. 2021:1-3. Available
1141 from <https://www.cdc.gov/vhf/index.html>
- 1142
1143 3. Isaäcson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis.
1144 2001;33(10):1707-1712. Epub 2001/10/12. doi: 10.1086/322620.
- 1145
1146 4. WHO. Rift Valley Fever. WHO Fact Sheet No 207. 2018:1-5. Epub 19 Feb 2018.
- 1147
1148 5. Munyua P, Murithi RM, Wainwright S, Githinji J, Hightower A, Mutonga D, et al. Rift
1149 Valley fever outbreak in livestock in Kenya, 2006-2007. Am J Trop Med Hyg. 2010;83(2
1150 Suppl):58-64. Epub 2010/08/13. doi: 10.4269/ajtmh.2010.09-0292.
- 1151
1152 6. CDC. Outbreak of Rift Valley fever--Yemen, August-October 2000. MMWR.
1153 2000;49(47):1065-1066.
- 1154
1155 7. Woods CW, Karpati AM, Grein T, McCarthy N, Gaturuku P, Muchiri E, et al. An
1156 outbreak of Rift Valley fever in Northeastern Kenya, 1997-98. Emerg Infect Dis.
1157 2002;8(2):138-144. Epub 2002/03/19. doi: 10.3201/eid0802.010023.
- 1158
1159 8. Daubney R, Hudson JR, Garnham PC. Enzootic hepatitis or Rift Valley fever: an
1160 undescribed virus disease of sheep, cattle and man from East Africa. Journal of
1161 Pathology and Bacteriology. 1931;34:545-579.
- 1162
1163 9. CDC. Update: Outbreak of Rift Valley Fever - Saudi Arabia, August-November 2000.
1164 MMWR. 2000;49(43):982-985.
- 1165
1166 10. Golnar AJ, Turell MJ, LaBeaud AD, Kading RC, Hamer GL. Predicting the mosquito
1167 species and vertebrate species involved in the theoretical transmission of Rift Valley
1168 fever virus in the United States. PLoS Negl Trop Dis. 2014;8(9):e3163. doi:
1169 10.1371/journal.pntd.0003163.

1170

- 1171 11. Iranpour M, Turell MJ, Lindsay LR. Potential for Canadian mosquitoes to transmit
1172 Rift Valley fever virus. J Am Mosq Control Assoc. 2011;27(4):363-369. Epub
1173 2012/02/15. doi: 10.2987/11-6169.1.
- 1174
1175 12. Turell MJ, Dohm DJ, Geden CJ, Hogsette JA, Linthicum KJ. Potential for stable flies
1176 and house flies (Diptera: Muscidae) to transmit Rift Valley fever virus. J Am Mosq
1177 Control Assoc. 2010;26(4):445-448. Epub 2011/02/05. doi: 10.2987/10-6070.1.
- 1178
1179 13. Turell MJ, Wilson WC, Bennett KE. Potential for North American mosquitoes
1180 (Diptera: Culicidae) to transmit Rift Valley fever virus. J Med Entomol. 2010;47(5):884-
1181 889. Epub 2010/10/14. doi: 10.1603/me10007.
- 1182
1183 14. Gargan TP, 2nd, Clark GG, Dohm DJ, Turell MJ, Bailey CL. Vector potential of
1184 selected North American mosquito species for Rift Valley fever virus. Am J Trop Med
1185 Hyg. 1988;38(2):440-446. doi: 10.4269/ajtmh.1988.38.440.
- 1186
1187 15. Turell MJ, Bailey CL, Beaman JR. Vector competence of a Houston, Texas strain of
1188 *Aedes albopictus* for Rift Valley fever virus. J Am Mosq Control Assoc. 1988;4(1):94-96.
- 1189
1190 16. Chengula AA, Mdegela RH, Kasanga CJ. Socio-economic impact of Rift Valley
1191 fever to pastoralists and agro pastoralists in Arusha, Manyara and Morogoro regions in
1192 Tanzania. Springerplus. 2013;2:549. Epub 2013/11/21. doi: 10.1186/2193-1801-2-549.
- 1193
1194 17. Holleman C. The socio-economic implications of the livestock ban in Somaliland.
1195 Food Early Warning System, Assessment Mission to Somaliland. FEWS NET, Nairobi
1196 2002.
- 1197
1198 18. Muga GO, Onyango-Ouma W, Sang R, Affognon H. Sociocultural and economic
1199 dimensions of Rift Valley fever. Am J Trop Med Hyg. 2015;92(4):730-738. Epub
1200 2015/02/18. doi: 10.4269/ajtmh.14-0363.
- 1201
1202 19. Rich KM, Wanyoike F. An assessment of the regional and national socio-economic
1203 impacts of the 2007 Rift Valley fever outbreak in Kenya. Am J Trop Med Hyg. 2010;83(2
1204 Suppl):52-57. doi: 10.4269/ajtmh.2010.09-0291.
- 1205
1206 20. Riou O, Phillippe B, Jouan A, Coulibaly I, Mondo M, Digoutte JP. Les formes
1207 neurologiques et neurosensorielles de la fièvre de Valley du Rift en Mauritanie. Bulletin
1208 de la Societe de Phologie Exotiques. 1989;82:605-610.
- 1209

- 1210 21. Kahlon SS, Peters CJ, Leduc J, Muchiri EM, Muiruri S, Njenga MK, et al. Severe
1211 Rift Valley fever may present with a characteristic clinical syndrome. *Am J Trop Med*
1212 *Hyg.* 2010;82(3):371-375. doi: 10.4269/ajtmh.2010.09-0669.
- 1213
1214 22. Kim Y, Metras R, Dommergues L, Youssouffi C, Combo S, Le Godais G, et al. The
1215 role of livestock movements in the spread of Rift Valley fever virus in animals and
1216 humans in Mayotte, 2018-19. *PLoS Negl Trop Dis.* 2021;15(3):e0009202. doi:
1217 10.1371/journal.pntd.0009202.
- 1218
1219 23. OIE. Rift Valley Fever (RVF): OIE; 2021. Available from:
1220 <https://www.oie.int/en/animal-health-in-the-world/animal-diseases/rift-valley-fever/>.
- 1221
1222 24. Davies FG, Linthicum KJ, James AD. Rainfall and epizootic Rift Valley Fever. *Bull*
1223 *World Health Organ.* 1985;63:941-943.
- 1224
1225 25. Linthicum KJ, Anyamba A, Tucker CJ, Kelley PW, Myers MF, Peters CJ. Climate
1226 and satellite indicators to forecast Rift Valley fever epidemics in Kenya. *Science.*
1227 1999;285:397-400.
- 1228
1229 26. Linthicum KJ, Bailey CL, Davies FG, Tucker CJ. Detection of Rift Valley fever viral
1230 activity in Kenya by satellite remote sensing imagery. *Science.* 1987;235(4796):1656-
1231 1659. Epub 1987/03/27.
- 1232
1233 27. Linthicum KJ, Bailey CL, Tucker CJ, Mitchell KD, Logan TM, Davies FG, et al.
1234 Application of polar-orbiting, meteorological satellite data to detect flooding of Rift Valley
1235 fever virus vector mosquito habitats in Kenya. *Med Vet Entomol.* 1990;4(4):433-438.
1236 Epub 1990/10/01.
- 1237
1238 28. Anyamba A, Chretien JP, Formenty PB, Small J, Tucker CJ, Malone JL, et al. Rift
1239 Valley fever potential, Arabian Peninsula. *Emerg Infect Dis.* 2006;12(3):518-520. Epub
1240 2006/05/23. doi: 10.3201/eid1203.050973.
- 1241
1242 29. Anyamba A, Chretien JP, Small J, Tucker CJ, Formenty PB, Richardson JH, et al.
1243 Prediction of a Rift Valley fever outbreak. *Proc Natl Acad Sci U S A.* 2009;106(3):955-
1244 959. doi: 10.1073/pnas.0806490106.
- 1245
1246 30. Anyamba A, Chretien JP, Small J, Tucker CJ, Linthicum KJ. Developing global
1247 climate anomalies suggest potential disease risks for 2006-2007. *Int J Health Geogr.*
1248 2006;5:60. Epub 2006/12/30. doi: 10.1186/1476-072x-5-60.

- 1249
1250 31. Anyamba A, Linthicum KJ, Small J, Britch SC, Pak E, de La Rocque S, et al.
1251 Prediction, assessment of the Rift Valley fever activity in East and southern Africa 2006-
1252 2008 and possible vector control strategies. *Am J Trop Med Hyg.* 2010;83(2 Suppl):43-
1253 51. doi: 10.4269/ajtmh.2010.09-0289.
- 1254
1255 32. Anyamba A, Linthicum KJ, Tucker CJ. Climate-disease connections: Rift Valley
1256 fever in Kenya. *Cad Saude Publica.* 2001;17 Suppl:133-140. Epub 2001/06/27. doi:
1257 10.1590/s0102-311x2001000700022.
- 1258
1259 33. Ahmed A, Makame J, Robert F, Julius K, Mecky M. Sero-prevalence and spatial
1260 distribution of Rift Valley fever infection among agro-pastoral and pastoral communities
1261 during interepidemic period in the Serengeti ecosystem, northern Tanzania. *BMC Infect*
1262 *Dis.* 2018;18(1):276. Epub 2018/06/15. doi: 10.1186/s12879-018-3183-9.
- 1263
1264 34. Tigoï C, Sang R, Chepkorir E, Orindi B, Arum SO, Mulwa F, et al. High risk for
1265 human exposure to Rift Valley fever virus in communities living along livestock
1266 movement routes: A cross-sectional survey in Kenya. *PLoS Negl Trop Dis.*
1267 2020;14(2):e0007979. Epub 2020/02/23. doi: 10.1371/journal.pntd.0007979.
- 1268
1269 35. Sanderson CE, Jori F, Moolla N, Paweska JT, Oumer N, Alexander KA. Silent
1270 circulation of Rift Valley fever in humans, Botswana, 2013-2014. *Emerg Infect Dis.*
1271 2020;26(10):2453-2456. Epub 2020/09/19. doi: 10.3201/eid2610.191837.
- 1272
1273 36. Schoepp RJ, Rossi CA, Khan SH, Goba A, Fair JN. Undiagnosed acute viral febrile
1274 illnesses, Sierra Leone. *Emerging Infectious Diseases.* 2014;20(7):1176-1182. doi:
1275 10.3201/eid2007.131265.
- 1276
1277 37. Bosworth A, Ghabbari T, Dowall S, Varghese A, Fares W, Hewson R, et al.
1278 Serologic evidence of exposure to Rift Valley fever virus detected in Tunisia. *New*
1279 *Microbes New Infect.* 2016;9:1-7. doi: 10.1016/j.nmni.2015.10.010.
- 1280
1281 38. Dellagi K, Salez N, Maquart M, Larrieu S, Yssouf A, Silai R, et al. Serological
1282 evidence of contrasted exposure to arboviral infections between islands of the Union of
1283 Comoros (Indian Ocean). *PloS Neglected Tropical Diseases.* 2016;10(12). doi:
1284 10.1371/journal.pntd.0004840.
- 1285
1286 39. Durand JP, Bouloy M, Richecoeur L, Peyrefitte CN, Tolou H. Rift Valley fever virus
1287 infection among French troops in Chad. *Emerg Infect Dis.* 2003;9(6):751-752. Epub
1288 2003/06/05. doi: 10.3201/eid0906.020647.

- 1289
1290 40. Guillebaud J, Bernardson B, Randriambolamanantsoa TH, Randrianasolo L,
1291 Randriamampionona JL, Marino CA, et al. Study on causes of fever in primary
1292 healthcare center uncovers pathogens of public health concern in Madagascar. PLoS
1293 Negl Trop Dis. 2018;12(7):e0006642. Epub 2018/07/17. doi:
1294 10.1371/journal.pntd.0006642.
- 1295
1296 41. Gudo ES, Pinto G, Weyer J, le Roux C, Mandlaze A, José AF, et al. Serological
1297 evidence of rift valley fever virus among acute febrile patients in Southern Mozambique
1298 during and after the 2013 heavy rainfall and flooding: implication for the management of
1299 febrile illness. Virol J. 2016;13:96. Epub 2016/06/10. doi: 10.1186/s12985-016-0542-2.
- 1300
1301 42. Sow A, Faye O, Faye O, Diallo D, Sadio BD, Weaver SC, et al. Rift Valley fever in
1302 Kedougou, southeastern Senegal, 2012. Emerg Infect Dis. 2014;20(3):504-506. Epub
1303 2014/02/26. doi: 10.3201/eid2003.131174.
- 1304
1305 43. Sumaye RD, Abatih EN, Thiry E, Amuri M, Berkvens D, Geubbels E. Inter-epidemic
1306 acquisition of Rift Valley fever virus in humans in Tanzania. PLoS Negl Trop Dis.
1307 2015;9(2):e0003536. Epub 2015/02/28. doi: 10.1371/journal.pntd.0003536.
- 1308
1309 44. Liu J, Sun Y, Shi W, Tan S, Pan Y, Cui S, et al. The first imported case of Rift
1310 Valley fever in China reveals a genetic reassortment of different viral lineages. Emerg
1311 Microbes Infect. 2017;6(1):e4. Epub 2017/01/18. doi: 10.1038/emi.2016.136.
- 1312
1313 45. Oltmann A, Kämper S, Staeck O, Schmidt-Chanasit J, Günther S, Berg T, et al.
1314 Fatal outcome of hepatitis A virus (HAV) infection in a traveler with incomplete HAV
1315 vaccination and evidence of Rift Valley fever virus infection. J Clin Microbiol.
1316 2008;46(11):3850-3852. Epub 2008/09/05. doi: 10.1128/jcm.01102-08.
- 1317
1318 46. Evans A, Gakuya F, Paweska JT, Rostal M, Akoolo L, Van Vuren PJ, et al.
1319 Prevalence of antibodies against Rift Valley fever virus in Kenyan wildlife. Epidemiology
1320 and Infection. 2008;136(9):1261-1269. doi: 10.1017/S0950268807009806.
- 1321
1322 47. LaBeaud AD, Cross PC, Getz WM, Glinka A, King CH. Rift Valley fever virus
1323 infection in African Buffalo (*Syncerus caffer*) herds in rural South Africa: Evidence of
1324 interepidemic transmission. American Journal of Tropical Medicine and Hygiene.
1325 2011;84(4):641-646. doi: 10.4269/ajtmh.2011.10-0187.
- 1326

- 1327 48. Olive MM, Goodman SM, Reynes JM. The role of wild mammals in the
1328 maintenance of Rift Valley fever virus. *J Wildl Dis.* 2012;48(2):241-266. doi:
1329 10.7589/0090-3558-48.2.241.
- 1330
- 1331 49. Rostal MK, Evans AL, Sang R, Gikundi S, Wakhule L, Munyua P, et al.
1332 Identification of potential vectors of and detection of antibodies against Rift Valley fever
1333 virus in livestock during interepizootic periods. *American Journal of Veterinary*
1334 *Research.* 2010;71(5):522-526. doi: 10.2460/ajvr.71.5.522.
- 1335
- 1336 50. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
1337 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
1338 *Bmj.* 2021;372:n71. doi: 10.1136/bmj.n71.
- 1339
- 1340 51. García-Bocanegra I, Paniagua J, Cano-Terriza D, Arenas-Montes A, Fernández-
1341 Morente M, Napp S. Absence of Rift Valley fever virus in domestic and wild ruminants
1342 from Spain. *Vet Rec.* 2016;179(2):48. Epub 2016/05/11. doi: 10.1136/vr.103696.
- 1343
- 1344 52. Mentaberre G, Gutierrez C, Rodriguez NF, Joseph S, Gonzalez-Barrio D, Cabezon
1345 O, et al. A transversal study on antibodies against selected pathogens in dromedary
1346 camels in the Canary Islands, Spain. *Veterinary Microbiology.* 2013;167(3-4):468-473.
1347 doi: 10.1016/j.vetmic.2013.07.029.
- 1348
- 1349 53. Bazanow BA, Stygar D, Romuk E, Skrzep-Poloczek B, Pacon J, Gadzala L, et al.
1350 Preliminary serological investigation of Rift Valley fever in Poland. *Journal of Vector*
1351 *Borne Diseases.* 2018;55(4):324-326. doi: 10.4103/0972-9062.256570.
- 1352
- 1353 54. Kim HJ, Park JY, Jeoung HY, Yeh JY, Cho YS, Choi JS, et al. Serological
1354 surveillance studies confirm the Rift Valley fever virus free status in South Korea. *Trop*
1355 *Anim Health Prod.* 2015;47(7):1427-1430. doi: 10.1007/s11250-015-0858-8.
- 1356
- 1357 55. Batieha A, Saliba EK, Graham R, Mohareb E, Hijazi Y, Wijeyaratne P.
1358 Seroprevalence of West Nile, Rift Valley, and sandfly arboviruses in Hashimiah, Jordan.
1359 *Emerg Infect Dis.* 2000;6(4):358-362. Epub 2000/07/25. doi: 10.3201/eid0604.000405.
- 1360
- 1361 56. Freeman MC, Garn JV, Sclar GD, Boisson S, Medlicott K, Alexander KT, et al. The
1362 impact of sanitation on infectious disease and nutritional status: A systematic review
1363 and meta-analysis. *Int J Hyg Environ Health.* 2017;220(6):928-949. doi:
1364 10.1016/j.ijheh.2017.05.007.
- 1365

- 1366 57. Puzzolo E, Pope D, Stanistreet D, Rehfuess EA, Bruce NG. Clean fuels for
1367 resource-poor settings: A systematic review of barriers and enablers to adoption and
1368 sustained use. *Environ Res.* 2016;146:218-234. doi: 10.1016/j.envres.2016.01.002.
- 1369
- 1370 58. Hardcastle AN, Osborne JCP, Ramshaw RE, Hulland EN, Morgan JD, Miller-Petrie
1371 MK, et al. Informing Rift Valley fever preparedness by mapping seasonally varying
1372 environmental suitability. *Int J Infect Dis.* 2020;99:362-372. Epub 2020/08/02. doi:
1373 10.1016/j.ijid.2020.07.043.
- 1374
- 1375 59. Redding DW, Tiedt S, Lo Iacono G, Bett B, Jones KE. Spatial, seasonal and
1376 climatic predictive models of Rift Valley fever disease across Africa. *Philos Trans R Soc
1377 Lond B Biol Sci.* 2017;372(1725). Epub 2017/06/07. doi: 10.1098/rstb.2016.0165.
- 1378
- 1379 60. Williams R, Malherbe J, Weepener H, Majiwa P, Swanepoel R. Anomalous high
1380 rainfall and soil saturation as combined risk indicator of Rift Valley fever outbreaks,
1381 South Africa, 2008-2011. *Emerg Infect Dis.* 2016;22(12):2054-2062. Epub 2016/07/13.
1382 doi: 10.3201/eid2212.151352.
- 1383
- 1384 61. Hightower A, Kinkade C, Nguku PM, Anyangu A, Mutonga D, Omolo J, et al.
1385 Relationship of climate, geography, and geology to the incidence of Rift Valley fever in
1386 Kenya during the 2006-2007 outbreak. *American Journal of Tropical Medicine and
1387 Hygiene.* 2012;86(2):373-380. doi: 10.4269/ajtmh.2012.11-0450.
- 1388
- 1389 62. Verster AM, Liang JE, Rostal MK, Kemp A, Brand RF, Anyamba A, et al. Selected
1390 wetland soil properties correlate to Rift Valley fever livestock mortalities reported in
1391 2009-10 in central South Africa. *PLoS One.* 2020;15(5):e0232481. Epub 2020/05/19.
1392 doi: 10.1371/journal.pone.0232481.
- 1393
- 1394 63. Sindato C, Pfeiffer DU, Karimuribo ED, Mboera LE, Rweyemamu MM, Paweska JT.
1395 A spatial analysis of Rift Valley fever virus seropositivity in domestic ruminants in
1396 Tanzania. *PLoS One.* 2015;10(7):e0131873. Epub 2015/07/15. doi:
1397 10.1371/journal.pone.0131873.
- 1398
- 1399 64. Nicholas DE, Jacobsen KH, Waters NM. Risk factors associated with human Rift
1400 Valley fever infection: systematic review and meta-analysis. *Trop Med Int Health.*
1401 2014;19(12):1420-1429. doi: 10.1111/tmi.12385.
- 1402
- 1403 65. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.*
1404 2002;21(11):1539-1558. Epub 2002/07/12. doi: 10.1002/sim.1186.
- 1405

- 1406 66. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining
1407 heterogeneity and combining results from several studies in meta-analysis. In: Egger M,
1408 Smith GD, Altman DG, editors. *Systematic Reviews in Health Care: Meta-analysis in*
1409 *Context*. London: BMJ Books; 2001. p. 285-312.
- 1410
1411 67. Clark MHA, Warimwe GM, Di Nardo A, Lyons NA, Gubbins S. Systematic literature
1412 review of Rift Valley fever virus seroprevalence in livestock, wildlife and humans in
1413 Africa from 1968 to 2016. *PLoS Neglected Tropical Diseases*. 2018;12(7). doi:
1414 10.1371/journal.pntd.0006627.
- 1415
1416 68. LaBeaud AD, Muchiri EM, Ndzovu M, Mwanje MT, Muiruri S, Peters CJ, et al.
1417 Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya. *Emerg Infect*
1418 *Dis*. 2008;14(8):1240-1246. doi: 10.3201/eid1408.080082.
- 1419
1420 69. McElroy AK, Albariño CG, Nichol ST. Development of a RVFV ELISA that can
1421 distinguish infected from vaccinated animals. *Virol J*. 2009;6:125. Epub 2009/08/15. doi:
1422 10.1186/1743-422x-6-125.
- 1423
1424 70. Paweska JT, Burt FJ, Swanepoel R. Validation of IgG-sandwich and IgM-capture
1425 ELISA for the detection of antibody to Rift Valley fever virus in humans. *J Virol Methods*.
1426 2005;124(1-2):173-181. Epub 2005/01/25. doi: 10.1016/j.jviromet.2004.11.020.
- 1427
1428 71. Paweska JT, Jansen van Vuren P, Swanepoel R. Validation of an indirect ELISA
1429 based on a recombinant nucleocapsid protein of Rift Valley fever virus for the detection
1430 of IgG antibody in humans. *J Virol Methods*. 2007;146(1-2):119-124. Epub 2007/07/25.
1431 doi: 10.1016/j.jviromet.2007.06.006.
- 1432
1433 72. Jansen van Vuren P, Paweska JT. Laboratory safe detection of nucleocapsid
1434 protein of Rift Valley fever virus in human and animal specimens by a sandwich ELISA.
1435 *J Virol Methods*. 2009;157(1):15-24. Epub 2009/01/07. doi:
1436 10.1016/j.jviromet.2008.12.003.
- 1437
1438 73. Wichgers Schreur PJ, Paweska JT, Kant J, Kortekaas J. A novel highly sensitive,
1439 rapid and safe Rift Valley fever virus neutralization test. *J Virol Methods*. 2017;248:26-
1440 30. doi: 10.1016/j.jviromet.2017.06.001.
- 1441
1442 74. Sobarzo A, Paweska JT, Herrmann S, Amir T, Marks RS, Lobel L. Optical fiber
1443 immunosensor for the detection of IgG antibody to Rift Valley fever virus in humans.
1444 *Journal of Virological Methods*. 2007;146(1-2):327-334. doi:
1445 10.1016/j.jviromet.2007.07.017.

- 1446
1447 75. van der Wal FJ, Achterberg RP, de Boer SM, Boshra H, Brun A, Maassen CB, et al.
1448 Bead-based suspension array for simultaneous detection of antibodies against the Rift
1449 Valley fever virus nucleocapsid and Gn glycoprotein. *J Virol Methods*. 2012;183(2):99-
1450 105. doi: 10.1016/j.jviromet.2012.03.008.
- 1451
1452 76. Petrova V, Kristiansen P, Norheim G, Yimer SA. Rift valley fever: diagnostic
1453 challenges and investment needs for vaccine development. *BMJ Glob Health*.
1454 2020;5(8). Epub 2020/08/21. doi: 10.1136/bmjgh-2020-002694.
- 1455
1456 77. Beechler BR, Manore CA, Reininghaus B, O'Neal D, Gorsich EE, Ezenwa VO, et al.
1457 Enemies and turncoats: bovine tuberculosis exposes pathogenic potential of Rift Valley
1458 fever virus in a common host, African buffalo (*Syncerus caffer*). *Proc Biol Sci*.
1459 2015;282(1805). Epub 2015/03/20. doi: 10.1098/rspb.2014.2942.
- 1460
1461 78. Capobianco Dondona A, Aschenborn O, Pinoni C, Di Gialleonardo L, Maseke A,
1462 Bortone G, et al. Rift Valley fever virus among wild ruminants, Etosha National Park,
1463 Namibia, 2011. *Emerg Infect Dis*. 2016;22(1):128-130. doi: 10.3201/eid2201.150725.
- 1464
1465 79. Sindato C, Swai ES, Karimuribo ED, Dautu G, Pfeiffer DU, Mboera LEG, et al.
1466 Spatial distribution of non-clinical Rift Valley fever viral activity in domestic and wild
1467 ruminants in northern Tanzania. *Tanzania Veterinary Journal*. 2013;28 (Special):21-38.
- 1468
1469 80. Selmi R, Mamlouk A, Ben Said M, Ben Yahia H, Abdelaali H, Ben Chehida F, et al.
1470 First serological evidence of the Rift Valley fever Phlebovirus in Tunisian camels. *Acta
1471 Trop*. 2020;207:105462. Epub 2020/04/24. doi: 10.1016/j.actatropica.2020.105462.
- 1472
1473 81. Di Nardo A, Rossi D, Saleh SM, Lejlifa SM, Hamdi SJ, Di Gennaro A, et al.
1474 Evidence of Rift Valley fever seroprevalence in the Sahrawi semi-nomadic pastoralist
1475 system, Western Sahara. *BMC Vet Res*. 2014;10:92. Epub 2014/04/25. doi:
1476 10.1186/1746-6148-10-92.
- 1477
1478 82. Kanouté YB, Gagnon BG, Schindler C, Bonfoh B, Schelling E. Epidemiology of
1479 brucellosis, Q Fever and Rift Valley fever at the human and livestock interface in
1480 northern Côte d'Ivoire. *Acta Trop*. 2017;165:66-75. Epub 2016/02/24. doi:
1481 10.1016/j.actatropica.2016.02.012.
- 1482
1483 83. Andayi F, Charrel RN, Kieffer A, Richet H, Pastorino B, Leparç-Goffart I, et al. A
1484 sero-epidemiological study of arboviral fevers in Djibouti, Horn of Africa. *PLoS Negl
1485 Trop Dis*. 2014;8(12):e3299. Epub 2014/12/17. doi: 10.1371/journal.pntd.0003299.

- 1486
1487 84. Umehoza T, Berkvens D, Gafarasi I, Rukelibuga J, Mushonga B, Biryomumaisho S.
1488 Seroprevalence of Rift Valley fever in cattle along the Akagera-Nyabarongo rivers,
1489 Rwanda. *J S Afr Vet Assoc.* 2017;88(0):e1-e5. doi: 10.4102/jsava.v88i0.1379.
- 1490
1491 85. Dutuze MF, Ingabire A, Gafarasi I, Uwituze S, Nzayirambaho M, Christofferson RC.
1492 Identification of Bunyamwera and possible other Orthobunyavirus infections and
1493 disease in cattle during a Rift Valley fever outbreak in Rwanda in 2018. *Am J Trop Med*
1494 *Hyg.* 2020;103(1):183-189. Epub 2020/04/22. doi: 10.4269/ajtmh.19-0596.
- 1495
1496 86. Bonney JH, Osei-Kwasi M, Adiku TK, Barnor JS, Amesiya R, Kubio C, et al.
1497 Hospital-based surveillance for viral hemorrhagic fevers and hepatitides in Ghana.
1498 *PLoS Negl Trop Dis.* 2013;7(9):e2435. Epub 2013/09/27. doi:
1499 10.1371/journal.pntd.0002435.
- 1500
1501 87. Bird BH, Githinji JW, Macharia JM, Kasiiti JL, Muriithi RM, Gacheru SG, et al.
1502 Multiple virus lineages sharing recent common ancestry were associated with a large
1503 Rift Valley fever outbreak among livestock in Kenya during 2006-2007. *J Virol.*
1504 2008;82(22):11152-11166. doi: 10.1128/JVI.01519-08.
- 1505
1506 88. Miller BR, Godsey MS, Crabtree MB, Savage HM, Al-Mazrao Y, Al-Jeffri MH, et al.
1507 Isolation and genetic characterization of Rift Valley fever virus from *Aedes vexans*
1508 *arabiensis*, Kingdom of Saudi Arabia. *Emerg Infect Dis.* 2002;8(12):1492-1494. Epub
1509 2002/12/25. doi: 10.3201/eid0812.020194.
- 1510
1511 89. Nderitu L, Lee JS, Omolo J, Omulo S, O'Guinn ML, Hightower A, et al. Sequential
1512 Rift Valley fever outbreaks in eastern Africa caused by multiple lineages of the virus. *J*
1513 *Infect Dis.* 2011;203(5):655-665. doi: 10.1093/infdis/jjq004.
- 1514
1515 90. Maquart M, Pascalis H, Abdouroihmane S, Roger M, Abdourahime F, Cardinale E,
1516 et al. Phylogeographic reconstructions of a Rift Valley fever virus strain reveals
1517 transboundary animal movements from eastern continental Africa to the Union of the
1518 Comoros. *Transbound Emerg Dis.* 2016;63(2):e281-285. Epub 2014/09/13. doi:
1519 10.1111/tbed.12267.
- 1520
1521 91. Ratovonjato J, Olive MM, Tantely LM, Andrianaivolambo L, Tata E, Razainirina J, et
1522 al. Detection, isolation, and genetic characterization of Rift Valley fever virus from
1523 *Anopheles (Anopheles) coustani*, *Anopheles (Anopheles) squamosus*, and *Culex*
1524 (*Culex*) *antennatus* of the Haute Matsiatra region, Madagascar. *Vector Borne Zoonotic*
1525 *Dis.* 2011;11(6):753-759. Epub 2010/10/30. doi: 10.1089/vbz.2010.0031.

- 1526
1527 92. Andriamandimby SF, Randrianarivo-Solofoniaina AE, Jeanmaire EM,
1528 Ravololomanana L, Razafimanantsoa LT, Rakotojoelinandrasana T, et al. Rift Valley
1529 fever during rainy seasons, Madagascar, 2008 and 2009. *Emerg Infect Dis.*
1530 2010;16(6):963-970. doi: 10.3201/eid1606.091266.
- 1531
1532 93. Faye O, Ba H, Ba Y, Freire CC, Faye O, Ndiaye O, et al. Reemergence of Rift
1533 Valley fever, Mauritania, 2010. *Emerg Infect Dis.* 2014;20(2):300-303. Epub 2014/01/23.
1534 doi: 10.3201/eid2002.130996.
- 1535
1536 94. Sow A, Faye O, Ba Y, Diallo D, Fall G, Faye O, et al. Widespread Rift Valley fever
1537 emergence in Senegal in 2013-2014. *Open Forum Infect Dis.* 2016;3(3):ofw149. Epub
1538 2016/10/06. doi: 10.1093/ofid/ofw149.
- 1539
1540 95. Sow A, Faye O, Ba Y, Ba H, Diallo D, Faye O, et al. Rift Valley fever outbreak,
1541 southern Mauritania, 2012. *Emerg Infect Dis.* 2014;20(2):296-299. Epub 2014/01/23.
1542 doi: 10.3201/eid2002.131000.
- 1543
1544 96. Lagare A, Fall G, Ibrahim A, Ousmane S, Sadio B, Abdoulaye M, et al. First
1545 occurrence of Rift Valley fever outbreak in Niger, 2016. *Vet Med Sci.* 2019;5(1):70-78.
1546 Epub 2018/11/10. doi: 10.1002/vms3.135.
- 1547
1548 97. Grobbelaar AA, Weyer J, Leman PA, Kemp A, Paweska JT, Swanepoel R.
1549 Molecular epidemiology of Rift Valley fever virus. *Emerg Infect Dis.* 2011;17(12):2270-
1550 2276. Epub 2011/12/17. doi: 10.3201/eid1712.111035.
- 1551
1552 98. van Schalkwyk A, Gwala S, Schuck KN, Quan M, Davis AS, Romito M, et al.
1553 Retrospective phylogenetic analyses of formalin-fixed paraffin-embedded samples from
1554 the 2011 Rift Valley fever outbreak in South Africa, through sequencing of targeted
1555 regions. *J Virol Methods.* 2020;287:114003. Epub 2020/11/10. doi:
1556 10.1016/j.jviromet.2020.114003.
- 1557
1558 99. van Schalkwyk A, Romito M. Genomic characterization of Rift Valley fever virus,
1559 South Africa, 2018. *Emerg Infect Dis.* 2019;25(10):1979-1981. Epub 2019/09/21. doi:
1560 10.3201/eid2510.181748.
- 1561
1562 100. Liu W, Sun FJ, Tong YG, Zhang SQ, Cao WC. Rift Valley fever virus imported into
1563 China from Angola. *Lancet Infect Dis.* 2016;16(11):1226. Epub 2016/10/30. doi:
1564 10.1016/s1473-3099(16)30401-7.
- 1565

- 1566 101. Grobbelaar AA, Weyer J, Leman P, Kemp A, Paweska JT. Phylogeny of Rift Valley
1567 fever virus isolates recovered from humans during 2008-2011 disease outbreaks in
1568 South Africa. *International Journal of Infectious Diseases*. 2014;21:224-224. doi:
1569 10.1016/j.ijid.2014.03.887.
- 1570
1571 102. Bett B, Said MY, Sang R, Bukachi S, Wanyoike S, Kifugo SC, et al. Effects of flood
1572 irrigation on the risk of selected zoonotic pathogens in an arid and semi-arid area in the
1573 eastern Kenya. *PLoS One*. 2017;12(5). doi: 10.1371/journal.pone.0172626.
- 1574
1575 103. LaBeaud AD, Muiruri S, Sutherland LJ, Dahir S, Gildengorin G, Morrill J, et al.
1576 Postepidemic analysis of Rift Valley fever virus transmission in northeastern Kenya: a
1577 village cohort study. *PLoS Negl Trop Dis*. 2011;5(8):e1265. doi:
1578 10.1371/journal.pntd.0001265.
- 1579
1580 104. Arishi H, Ageel A, Rahman MA, Al Hazmi A, Arishi AR, Ayoola B, et al. Update:
1581 Outbreak of Rift Valley fever - Saudi Arabia, August-November 2000 (Reprinted from
1582 *MMWR*, vol 49, pg 982-986, 2000). *Journal of the American Medical Association*.
1583 2000;284(23):2989-2990.
- 1584
1585 105. Rift Valley fever, Saudi Arabia, August-October 2000. *Wkly Epidemiol Rec*.
1586 2000;75(46):370-371. Epub 2001/01/06.
- 1587
1588 106. Outbreak of Rift Valley fever, Yemen, August-October 2000. *Wkly Epidemiol Rec*.
1589 2000;75(48):392-395. Epub 2001/01/06.
- 1590
1591 107. Hanafi HA, Fryauff DJ, Saad MD, Soliman AK, Mohareb EW, Medhat I, et al. Virus
1592 isolations and high population density implicate *Culex antennatus* (Becker) (Diptera:
1593 Culicidae) as a vector of Rift Valley fever virus during an outbreak in the Nile Delta of
1594 Egypt. *Acta Trop*. 2011;119(2-3):119-124. Epub 2011/05/17. doi:
1595 10.1016/j.actatropica.2011.04.018.
- 1596
1597 108. Faye O, Diallo M, Diop D, Bezeid OE, Bâ H, Niang M, et al. Rift Valley fever
1598 outbreak with East-Central African virus lineage in Mauritania, 2003. *Emerg Infect Dis*.
1599 2007;13(7):1016-1023. Epub 2008/01/25. doi: 10.3201/eid1307.061487.
- 1600
1601 109. Sindato C, Karimuribo ED, Pfeiffer DU, Mboera LE, Kivaria F, Dautu G, et al.
1602 Spatial and temporal pattern of Rift Valley fever outbreaks in Tanzania; 1930 to 2007.
1603 *PLoS One*. 2014;9(2):e88897. Epub 2014/03/04. doi: 10.1371/journal.pone.0088897.
- 1604

- 1605 110. El Mamy AB, Baba MO, Barry Y, Isselmou K, Dia ML, El Kory MO, et al.
1606 Unexpected Rift Valley fever outbreak, northern Mauritania. *Emerg Infect Dis.*
1607 2011;17(10):1894-1896. Epub 2011/10/18. doi: 10.3201/eid1710.110397.
- 1608
1609 111. El Mamy AB, Kane Y, El Arbi AS, Barry Y, Bernard C, Lancelot R, et al. L'épidémie
1610 de la fièvre de la Vallé du Rift en 2012 en Mauritanie. *Revue Africaine de Santé et*
1611 *Productions Animales.* 2014;12(3-4):169-173.
- 1612
1613 112. Shoemaker T, Balinandi S, Nyakarahuka L, Ojwang J, Tumusiime A, Mulei S, et al.
1614 First laboratory confirmation of an outbreak of Rift Valley fever virus in 50 Years in
1615 Kabale District, southwestern Uganda. *American Journal of Tropical Medicine and*
1616 *Hygiene.* 2017;95(5):437-437.
- 1617
1618 113. Hassan A, Muturi M, Mwatondo A, Omolo J, Bett B, Gikundi S, et al.
1619 Epidemiological investigation of a Rift Valley fever outbreak in humans and livestock in
1620 Kenya, 2018. *Am J Trop Med Hyg.* 2020;103(4):1649-1655. Epub 2020/08/05. doi:
1621 10.4269/ajtmh.20-0387.
- 1622
1623 114. Youssouf H, Subiros M, Denetiere G, Collet L, Dommergues L, Pauvert A, et al.
1624 Rift Valley fever outbreak, Mayotte, France, 2018-2019. *Emerg Infect Dis.*
1625 2020;26(4):769-772. Epub 2020/03/19. doi: 10.3201/eid2604.191147.
- 1626
1627 115. van Vuren PJ, Kgaladi J, Patharoo V, Ohaebosim P, Msimang V, Nyokong B, et al.
1628 Human cases of Rift Valley fever in South Africa, 2018. *Vector-Borne and Zoonotic*
1629 *Diseases.* 2018;18(12):713-715. doi: 10.1089/vbz.2018.2357.
- 1630
1631 116. Youssef HM, Ghoneim MA, al. e. Recent trends for diagnosis of Rift Valley
1632 fever in animals and mosquitoes in Egypt with special reference to the carrier.
1633 *Global Veterinaria.* 2008;2(1).
- 1634
1635 117. Jeffries CL, Tantely LM, Raharimalala FN, Hurn E, Boyer S, Walker T. Diverse
1636 novel resident *Wolbachia* strains in Culicine mosquitoes from Madagascar. *Scientific*
1637 *Reports.* 2018;8. doi: 10.1038/s41598-018-35658-z.
- 1638
1639 118. Ndiaye EH, Diallo D, Fall G, Ba Y, Faye O, Dia I, et al. Arboviruses isolated from
1640 the Barkedji mosquito-based surveillance system, 2012-2013. *BMC Infect Dis.*
1641 2018;18(1):642. Epub 2018/12/14. doi: 10.1186/s12879-018-3538-2.
- 1642

- 1643 119. Abdelgadir DM, Bashab HMM, Mohamed RAE, Abuelmaali SA. Risk factor
1644 analysis for outbreak of Rift Valley fever in Khartoum State of Sudan. *Journal of*
1645 *Entomological Science*. 2010;45(3):239-251. doi: 10.18474/0749-8004-45.3.239.
- 1646
- 1647 120. Mbanzulu KM, Mboera LEG, Luzolo FK, Wumba R, Misinzo G, Kimera SI.
1648 Mosquito-borne viral diseases in the Democratic Republic of the Congo: a review.
1649 *Parasit Vectors*. 2020;13(1):103. Epub 2020/02/28. doi: 10.1186/s13071-020-3985-7.
- 1650
- 1651 121. Mohamed RAE, Mohamed N, Aleanizy FS, Alqahtani FY, Al Khalaf A, Al-Keridis
1652 LA. Investigation of hemorrhagic fever viruses inside wild populations of ticks: One of
1653 the pioneer studies in Saudi Arabia. *Asian Pacific Journal of Tropical Disease*.
1654 2017;7:299-303.
- 1655
- 1656 122. Mohamed M, Mosha F, Mghamba J, Zaki SR, Shieh WJ, Paweska J, et al.
1657 Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in
1658 Tanzania, 2007. *Am J Trop Med Hyg*. 2010;83(2 Suppl):22-27. doi:
1659 10.4269/ajtmh.2010.09-0318.
- 1660
- 1661 123. LaBeaud AD, Pfeil S, Muiruri S, Dahir S, Sutherland LJ, Traylor Z, et al. Factors
1662 associated with severe human Rift Valley fever in Sangailu, Garissa County, Kenya.
1663 *PLoS Negl Trop Dis*. 2015;9(3):e0003548. Epub 2015/03/13. doi:
1664 10.1371/journal.pntd.0003548.
- 1665
- 1666 124. Anyangu AS, Gould LH, Sharif SK, Nguku PM, Omolo JO, Mutonga D, et al. Risk
1667 factors for severe Rift Valley fever infection in Kenya, 2007. *Am J Trop Med Hyg*.
1668 2010;83(2 Suppl):14-21. doi: 10.4269/ajtmh.2010.09-0293.
- 1669
- 1670 125. Seufi AM, Galal FH. Role of *Culex* and *Anopheles* mosquito species as potential
1671 vectors of Rift Valley fever virus in Sudan outbreak, 2007. *BMC Infect Dis*. 2010;10:65.
1672 Epub 2010/03/13. doi: 10.1186/1471-2334-10-65.
- 1673
- 1674 126. Oyas H, Holmstrom L, Kemunto NP, Muturi M, Mwatondo A, Osoro E, et al.
1675 Enhanced surveillance for Rift Valley fever in livestock during El Niño rains and threat of
1676 RVF outbreak, Kenya, 2015-2016. *PLoS Negl Trop Dis*. 2018;12(4):e0006353. Epub
1677 2018/04/27. doi: 10.1371/journal.pntd.0006353.
- 1678
- 1679 127. Bashir RSE, Hassan OA. A One Health perspective to identify environmental
1680 factors that affect Rift Valley fever transmission in Gezira state, Central Sudan. *Tropical*
1681 *Medicine and Health*. 2019;47(1). doi: 10.1186/s41182-019-0178-1.
- 1682

- 1683 128. van Vuren PJ, Shalekoff S, Grobbelaar AA, Archer BN, Thomas J, Tiemessen CT,
1684 et al. Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative
1685 of severe disease. *Virology Journal*. 2015;12. doi: 10.1186/s12985-015-0392-3.
- 1686
- 1687 129. Outbreak news. Rift Valley fever, Kenya. *Wkly Epidemiol Rec*. 2007;82(3):17-18.
1688 Epub 2007/01/24.
- 1689
- 1690 130. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani
1691 AM, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and
1692 laboratory characteristics. *Clin Infect Dis*. 2003;37(8):1084-1092. doi: 10.1086/378747.
- 1693
- 1694 131. Njenga MK, Paweska J, Wanjala R, Rao CY, Weiner M, Omballa V, et al. Using a
1695 field quantitative real-time PCR test to rapidly identify highly viremic rift valley fever
1696 cases. *J Clin Microbiol*. 2009;47(4):1166-1171. Epub 2009/01/28. doi:
1697 10.1128/jcm.01905-08.
- 1698
- 1699 132. Bett B, Lindahl J, Sang R, Wainaina M, Kairu-Wanyoike S, Bukachi S, et al.
1700 Association between Rift Valley fever virus seroprevalences in livestock and humans
1701 and their respective intra-cluster correlation coefficients, Tana River County, Kenya.
1702 *Epidemiology and Infection*. 2019;147. doi: 10.1017/S0950268818003242.
- 1703
- 1704 133. Nicolas G, Chevalier V, Tantely LM, Fontenille D, Durand B. A spatially explicit
1705 metapopulation model and cattle trade analysis suggests key determinants for the
1706 recurrent circulation of Rift Valley fever virus in a pilot area of Madagascar highlands.
1707 *PLoS Negl Trop Dis*. 2014;8(12):e3346. doi: 10.1371/journal.pntd.0003346.
- 1708
- 1709 134. Metras R, Cavalerie L, Dommergues L, Merot P, Edmunds WJ, Keeling MJ, et al.
1710 The epidemiology of Rift Valley fever in Mayotte: insights and perspectives from 11
1711 years of data. *PLoS Neglected Tropical Diseases*. 2016;10(6). doi:
1712 10.1371/journal.pntd.0004783.
- 1713
- 1714 135. Alhaj M. Surveillance study on Rift Valley fever in Jazan region, Saudi Arabia. *Int J*
1715 *Adv Sci Tech Res*. 2015;5(4):1-13.
- 1716
- 1717 136. Ngoshe YB, Avenant A, Rostal MK, Karesh WB, Paweska JT, Bagge W, et al.
1718 Patterns of Rift Valley fever virus seropositivity in domestic ruminants in central South
1719 Africa four years after a large outbreak. *Scientific Reports*. 2020;10(1). doi:
1720 10.1038/s41598-020-62453-6.
- 1721

- 1722 137. Moiane B, Mapaco L, Thompson P, Berg M, Albihn A, Fafetine J. High
1723 seroprevalence of Rift Valley fever phlebovirus in domestic ruminants and African
1724 Buffaloes in Mozambique shows need for intensified surveillance. *Infect Ecol Epidemiol.*
1725 2017;7(1):1416248. Epub 2018/01/13. doi: 10.1080/20008686.2017.1416248.
- 1726
1727 138. Caron A, Cornelis D, Foggin C, Hofmeyr M, de Garine-Wichatitsky M. African
1728 Buffalo movement and zoonotic disease risk across transfrontier conservation areas,
1729 Southern Africa. *Emerg Infect Dis.* 2016;22(2):277-280. Epub 2016/01/27. doi:
1730 10.3201/eid2202.140864.
- 1731
1732 139. Byomi AM, Samaha HA, Zidan SA, Hadad GA. Some associated risk factors with
1733 the occurrence of Rift Valley fever in animals and man in certain localities of Nile delta,
1734 Egypt. *Assiut Veterinary Medical Journal.* 2015;61:10-17.
- 1735
1736 140. Mohamed AM, Ashshi AM, Asghar AH, Abd El-Rahim IH, El-Shemi AG, Zafar T.
1737 Seroepidemiological survey on Rift Valley fever among small ruminants and their close
1738 human contacts in Makkah, Saudi Arabia, in 2011. *Rev Sci Tech.* 2014;33(3):903-915.
1739 doi: 10.20506/rst.33.3.2328.
- 1740
1741 141. Wensman JJ, Lindahl J, Wachtmeister N, Torsson E, Gwakisa P, Kasanga C, et
1742 al. A study of Rift Valley fever virus in Morogoro and Arusha regions of Tanzania -
1743 serology and farmers' perceptions. *Infect Ecol Epidemiol.* 2015;5:30025. doi:
1744 10.3402/iee.v5.30025.
- 1745
1746 142. Elfadil AA, Hasab-Allah KA, Dafa-Allah OM. Factors associated with Rift Valley
1747 fever in south-west Saudi Arabia. *Rev Sci Tech.* 2006;25(3):1137-1145.
- 1748
1749 143. Mdlulwa Z, Ngwane CB. Evaluating the impact of 2010 Rift Valley fever outbreaks
1750 on sheep numbers in three provinces of South Africa. *African Journal of Agricultural*
1751 *Research.* 2017;12(11):979-986.
- 1752
1753 144. Mroz C, Gwida M, El-Ashker M, Ziegler U, Homeier-Bachmann T, Eiden M, et al.
1754 Rift Valley fever virus infections in Egyptian cattle and their prevention. *Transbound*
1755 *Emerg Dis.* 2017;64(6):2049-2058. Epub 2017/01/25. doi: 10.1111/tbed.12616.
- 1756
1757 145. Abbas B, Yousif MA, M. NH. Animal health constraints to livestock exports from
1758 the Horn of Africa. *Rev Sci Tech.* 2014;33(3): 711-721.
- 1759

- 1760 146. Mohamed AM, Ghazi H, Ashshi AM, Faidah HS, Clinical EIA. Serological survey of
1761 Rift Valley fever among sacrifice animals in holy Mecca during pilgrimage season. . Int J
1762 Trop Med. 2011;6(4):85–89.
- 1763
1764 147. Tong C, Javelle E, Grard G, Dia A, Lacrosse C, Fourié T, et al. Tracking Rift Valley
1765 fever: From Mali to Europe and other countries, 2016. Euro Surveill. 2019;24(8). Epub
1766 2019/02/28. doi: 10.2807/1560-7917.es.2019.24.8.1800213.
- 1767
1768 148. Liu B, Ma J, Jiao Z, Gao X, Xiao J, Wang H. Risk assessment for the Rift Valley
1769 fever occurrence in China: Special concern in south-west border areas. Transbound
1770 Emerg Dis. 2020. Epub 2020/06/23. doi: 10.1111/tbed.13695.
- 1771
1772 149. Grossi-Soyster EN, LaBeaud AD. Rift Valley fever: Important considerations for
1773 risk mitigation and future outbreaks. Trop Med Infect Dis. 2020;5(2). doi:
1774 10.3390/tropicalmed5020089.
- 1775
1776 150. O'Hearn AE, Voorhees MA, Fetterer DP, Wauquier N, Coomber MR, Bangura J, et
1777 al. Serosurveillance of viral pathogens circulating in West Africa. Virol J.
1778 2016;13(1):163. Epub 2016/10/08. doi: 10.1186/s12985-016-0621-4.
- 1779
1780 151. LaBeaud AD, Ochiai Y, Peters CJ, Muchiri EM, King CH. Spectrum of Rift Valley
1781 fever virus transmission in Kenya: Insights from three distinct regions. American Journal
1782 of Tropical Medicine and Hygiene. 2007;76(5):795-800. doi:
1783 10.4269/ajtmh.2007.76.795.
- 1784
1785 152. Grossi-Soyster EN, Banda T, Teng CY, Muchiri EM, Mungai PL, Mutuku FM, et al.
1786 Rift Valley fever seroprevalence in coastal Kenya. Am J Trop Med Hyg. 2017;97(1):115-
1787 120. Epub 2017/07/19. doi: 10.4269/ajtmh.17-0104.
- 1788
1789 153. Cook EAJ, Grossi-Soyster EN, de Glanville WA, Thomas LF, Kariuki S, Bronsvort
1790 BMD, et al. The sero-epidemiology of Rift Valley fever in people in the Lake Victoria
1791 Basin of western Kenya. Plos Neglected Tropical Diseases. 2017;11(7). doi:
1792 10.1371/journal.pntd.0005731.
- 1793
1794 154. Gray GC, Anderson BD, LaBeaud AD, Heraud JM, Fevre EM, Andriamandimby
1795 SF, et al. Seroepidemiological study of interepidemic Rift Valley fever virus infection
1796 among persons with intense ruminant exposure in Madagascar and Kenya. Am J Trop
1797 Med Hyg. 2015;93(6):1364-1370. doi: 10.4269/ajtmh.15-0383.
- 1798

- 1799 155. LaBeaud AD, Bashir F, King CH. Measuring the burden of arboviral diseases: the
1800 spectrum of morbidity and mortality from four prevalent infections. *Population Health*
1801 *Metrics*. 2011;9. doi: 10.1186/1478-7954-9-1.
- 1802
- 1803 156. Muiruri S, Kabiru EW, Muchiri EM, Hussein H, Kagonda F, LaBeaud AD, et al.
1804 Cross-sectional survey of Rift Valley fever virus exposure in Bodhei village located in a
1805 transitional coastal forest habitat in Lamu County, Kenya. *Am J Trop Med Hyg*.
1806 2015;92(2):394-400. Epub 2014/12/24. doi: 10.4269/ajtmh.14-0440.
- 1807
- 1808 157. Nanyingi MO, Munyua P, Kiama SG, Muchemi GM, Thumbi SM, Bitek AO, et al. A
1809 systematic review of Rift Valley fever epidemiology 1931-2014. *Infect Ecol Epidemiol*.
1810 2015;5:28024. Epub 2015/08/04. doi: 10.3402/iee.v5.28024.
- 1811
- 1812 158. Jori F, Godfroid J, Michel AL, Potts AD, Jaumally MR, Sauzier J, et al. An
1813 assessment of zoonotic and production limiting pathogens in rusa deer (*Cervus*
1814 *timorensis rusa*) from Mauritius. *Transbound Emerg Dis*. 2014;61 Suppl 1:31-42. doi:
1815 10.1111/tbed.12206.
- 1816
- 1817 159. Elfving K, Shakely D, Andersson M, Baltzell K, Ali AS, Bachelard M, et al. Acute
1818 uncomplicated febrile illness in children aged 2-59 months in Zanzibar - aetiologies,
1819 antibiotic treatment and outcome. *PLoS One*. 2016;11(1):e0146054. Epub 2016/01/29.
1820 doi: 10.1371/journal.pone.0146054.
- 1821
- 1822 160. Nicolas G, Durand B, Duboz R, Rakotondravao R, Chevalier V. Description and
1823 analysis of the cattle trade network in the Madagascar highlands: potential role in the
1824 diffusion of Rift Valley fever virus. *Acta Trop*. 2013;126(1):19-27. doi:
1825 10.1016/j.actatropica.2012.12.013.
- 1826
- 1827 161. Abdo-Salem S, Tran A, Grosbois V, Gerbier G, Al-Qadasi M, Saeed K, et al. Can
1828 environmental and socioeconomic factors explain the recent emergence of Rift Valley
1829 fever in Yemen, 2000-2001? *Vector Borne Zoonotic Dis*. 2011;11(6):773-779. Epub
1830 2011/02/03. doi: 10.1089/vbz.2010.0084.
- 1831
- 1832 162. Xiao Y, Beier JC, Cantrell RS, Cosner C, DeAngelis DL, Ruan S. Modelling the
1833 effects of seasonality and socioeconomic impact on the transmission of Rift Valley fever
1834 virus. *PLoS Negl Trop Dis*. 2015;9(1):e33388. Epub 2015/01/09. doi:
1835 10.1371/journal.pntd.0003388.
- 1836

- 1837 163. Apolloni A, Nicolas G, Coste C, El Mamy AB, Yahya B, El Arbi AS, et al. Towards
1838 the description of livestock mobility in Sahelian Africa: Some results from a survey in
1839 Mauritania. PLoS One. 2018;13(1). doi: 10.1371/journal.pone.0191565.
- 1840
1841 164. Bergren NA, Borland EM, Hartman DA, Kading RC. Laboratory demonstration of
1842 the vertical transmission of Rift Valley fever virus by *Culex tarsalis* mosquitoes. PLoS
1843 Negl Trop Dis. 2021;15(3):e0009273. doi: 10.1371/journal.pntd.0009273.
- 1844
1845 165. Antonis AF, Kortekaas J, Kant J, Vloet RP, Vogel-Brink A, Stockhofe N, et al.
1846 Vertical transmission of Rift Valley fever virus without detectable maternal viremia.
1847 Vector Borne Zoonotic Dis. 2013;13(8):601-606. doi: 10.1089/vbz.2012.1160.
- 1848
1849 166. Adam I, Karsany MS. Case report: Rift Valley fever with vertical transmission in a
1850 pregnant Sudanese woman. J Med Virol. 2008;80(5):929. Epub 2008/03/25. doi:
1851 10.1002/jmv.21132.
- 1852
1853 167. Arishi HM, Aqeel AY, Al Hazmi MM. Vertical transmission of fatal Rift Valley fever
1854 in a newborn. Ann Trop Paediatr. 2006;26(3):251-253. doi:
1855 10.1179/146532806X120363.
- 1856
1857 168. Baudin M, Jumaa AM, Jomma HJE, Karsany MS, Bucht G, Näslund J, et al.
1858 Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a
1859 cross-sectional study. Lancet Glob Health. 2016;4(11):e864-e871. Epub 2016/10/22.
1860 doi: 10.1016/s2214-109x(16)30176-0.
- 1861
1862 169. Pienaar NJ, Thompson PN. Temporal and spatial history of Rift Valley fever in
1863 South Africa: 1950 to 2011. Onderstepoort J Vet Res. 2013;80(1):384. Epub
1864 2013/05/31. doi: 10.4102/ojvr.v80i1.384.
- 1865
1866 170. Ndengu M, Matope G, Tivapasi M, Pfukenyi DM, Cetre-Sossah C, De Garine-
1867 Wichtitsky M. Seroprevalence and associated risk factors of Rift Valley fever in cattle
1868 and selected wildlife species at the livestock/wildlife interface areas of Gonarezhou
1869 National Park, Zimbabwe. Onderstepoort J Vet Res. 2020;87(1):e1-e7. Epub
1870 2020/05/07. doi: 10.4102/ojvr.v87i1.1731.
- 1871
1872 171. Nyakarahuka L, de St Maurice A, Purpura L, Ervin E, Balinandi S, Tumusiime A, et
1873 al. Prevalence and risk factors of Rift Valley fever in humans and animals from Kabale
1874 district in Southwestern Uganda, 2016. PLoS Negl Trop Dis. 2018;12(5):e0006412.
1875 Epub 2018/05/04. doi: 10.1371/journal.pntd.0006412.
- 1876

- 1877 172. FAO. Rift Valley fever vaccine development, progress and constraints.
1878 Proceedings of the GF-TADs meeting, January 2011. Rome, Italy: 2011.
- 1879
1880 173. Bird BH, Nichol ST. Breaking the chain: Rift Valley fever virus control via livestock
1881 vaccination. *Curr Opin Virol.* 2012;2(3):315-323. Epub 2012/04/03. doi:
1882 10.1016/j.coviro.2012.02.017.
- 1883
1884 174. Shoemaker TR, Nyakarahuka L, Balinandi S, Ojwang J, Tumusiime A, Mulei S, et
1885 al. First laboratory-confirmed outbreak of human and animal Rift Valley fever virus in
1886 Uganda in 48 years. *Am J Trop Med Hyg.* 2019;100(3):659-671. Epub 2019/01/25. doi:
1887 10.4269/ajtmh.18-0732.
- 1888
1889 175. Archer BN, Weyer J, Paweska J, Nkosi D, Leman P, Tint KS, et al. Outbreak of
1890 Rift Valley fever affecting veterinarians and farmers in South Africa, 2008. *S Afr Med J.*
1891 2011;101(4):263-266. Epub 2011/07/27. doi: 10.7196/samj.4544.
- 1892
1893 176. Tambo E, Olalubi OA, Sacko M. Rift Valley fever epidemic in Niger near border
1894 with Mali. *Lancet Infectious Diseases.* 2016;16(12):1319-1320. doi: 10.1016/S1473-
1895 3099(16)30477-7.
- 1896
1897 177. Davies FG. Risk of a Rift Valley fever epidemic at the Hajj in Mecca, Saudi Arabia.
1898 *Rev Sci Tech.* 2006;25(1):137-147. doi: 10.20506/rst.25.1.1648.
- 1899
1900 178. Krystosik A, Njoroge G, Odhiambo L, Forsyth JE, Mutuku F, LaBeaud AD. Solid
1901 wastes provide breeding sites, burrows, and food for biological disease vectors, and
1902 urban zoonotic reservoirs: A call to action for solutions-based research. *Front Public*
1903 *Health.* 2019;7:405. doi: 10.3389/fpubh.2019.00405.
- 1904
1905 179. Salmon-Rousseau A, Piednoir E, Cattoir V, de La Blanchardiere A. Hajj-associated
1906 infections. *Medecine et Maladies Infectieuses.* 2016.
- 1907
1908 180. Cecilia H, Métras R, Fall AG, Lo MM, Lancelot R, Ezanno P. It's risky to wander in
1909 September: Modelling the epidemic potential of Rift Valley fever in a Sahelian setting.
1910 *Epidemics.* 2020;33:100409. Epub 2020/11/03. doi: 10.1016/j.epidem.2020.100409.
- 1911
1912 181. Obiero JPO, Onyando JO. Climate. Chapter 5 *in* *Developments in Earth Surface*
1913 *Processes.* 16 2013. p. 39-50.
- 1914

- 1915 182. Alhaji NB, Aminu J, Lawan MK, Babalobi OO, Ghali-Mohammed I, Odetokun IA.
1916 Seropositivity and associated intrinsic and extrinsic factors for Rift Valley fever virus
1917 occurrence in pastoral herds of Nigeria: a cross sectional survey. BMC Vet Res.
1918 2020;16(1):243. Epub 2020/07/16. doi: 10.1186/s12917-020-02455-8.
- 1919
1920 183. Durand B, Lo Modou M, Tran A, Ba A, Sow F, Belkhiria J, et al. Rift Valley fever in
1921 northern Senegal: A modelling approach to analyse the processes underlying virus
1922 circulation recurrence. Plos Neglected Tropical Diseases. 2020;14(6). doi:
1923 10.1371/journal.pntd.0008009.
- 1924
1925 184. Kakani S, LaBeaud AD, King CH. Planning for Rift Valley fever virus: use of
1926 geographical information systems to estimate the human health threat of white-tailed
1927 deer (*Odocoileus virginianus*)-related transmission. Geospat Health. 2010;5(1):33-43.
1928 doi: 10.4081/gh.2010.185.
- 1929
1930 185. Wilson WC, Kim IJ, Trujillo JD, Sunwoo SY, Noronha LE, Urbaniak K, et al.
1931 Susceptibility of white-tailed deer to Rift Valley fever virus. Emerg Infect Dis.
1932 2018;24(9):1717-1719. Epub 2018/08/21. doi: 10.3201/eid2409.180265.
- 1933
1934 186. Bron GM, Strimbu K, Cecilia H, Lerch A, Moore SM, Tran Q, et al. Over 100 Years
1935 of Rift Valley fever: A patchwork of data on pathogen spread and spillover. Pathogens.
1936 2021;10(6). doi: 10.3390/pathogens10060708.
- 1937
1938 187. Schwarz NG, Girmann M, Randriamampionona N, Bialonski A, Maus D, Krefis AC,
1939 et al. Seroprevalence of antibodies against chikungunya, dengue, and Rift Valley fever
1940 viruses after febrile illness outbreak, Madagascar. Emerg Infect Dis. 2012;18(11):1780-
1941 1786. doi: 10.3201/eid1811.111036.
- 1942
1943 188. Al-Qabati AG, Al-Afaleq AI. Cross-sectional, longitudinal and prospective
1944 epidemiological studies of Rift Valley fever in Al-Hasa Oasis, Saudi Arabia. Journal of
1945 Animal and Veterinary Advances. 2010;9(2):258-265.
- 1946
1947 189. Grossi-Soyster EN, Lee J, King CH, LaBeaud AD. The influence of raw milk
1948 exposures on Rift Valley fever virus transmission. PLoS Negl Trop Dis.
1949 2019;13(3):e0007258. doi: 10.1371/journal.pntd.0007258.
- 1950
1951 190. Cook EAJ, de Glanville WA, Thomas LF, Kariuki S, Bronsvort B, Fevre EM.
1952 Working conditions and public health risks in slaughterhouses in western Kenya. BMC
1953 Public Health. 2017;17. doi: 10.1186/s12889-016-3923-y.
- 1954

- 1955 191. Ikegami T, Balogh A, Nishiyama S, Lokugamage N, Saito TB, Morrill JC, et al.
1956 Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages
1957 in a mouse model. *PLoS One*. 2017;12(12):e0189250. Epub 2017/12/22. doi:
1958 10.1371/journal.pone.0189250.
- 1959
1960 192. WHO. Factors that contributed to undetected spread of the Ebola virus and
1961 impeded rapid containment. Geneva, Switzerland: World Health Organization; 2015
1962 [cited 2021 9/7/2021].
- 1963
1964 193. de St Maurice A, Nyakarahuka L, Purpura L, Ervin E, Tumusiime A, Balinandi S, et
1965 al. Notes from the field: Rift Valley fever response - Kabale District, Uganda, March
1966 2016. *MMWR Morb Mortal Wkly Rep*. 2016;65(43):1200-1201. Epub 2016/11/05. doi:
1967 10.15585/mmwr.mm6543a5.
- 1968
1969 194. Hartley DM, Rinderknecht JL, Nipp TL, Clarke NP, Snowden GD, National Center
1970 for Foreign Animal Zoonotic Disease Defense Advisory Group on Rift Valley Fever.
1971 Potential effects of Rift Valley fever in the United States. *Emerg Infect Dis*.
1972 2011;17(8):e1. doi: 10.3201/eid1708.101088.
- 1973
1974 195. Brugere-Picoux J, Chomel B. Importation of tropical diseases to Europe via
1975 animals and animal products: risks and pathways. *Bulletin de L Academie Nationale de*
1976 *Medecine*. 2009;193(8):1805-1819. doi: 10.1016/S0001-4079(19)32415-X.
- 1977
1978 196. Cito F, Narcisi V, Danzetta ML, Iannetti S, Sabatino DD, Bruno R, et al. Analysis of
1979 surveillance systems in place in European Mediterranean countries for West Nile virus
1980 (WNV) and Rift Valley fever (RVF). *Transbound Emerg Dis*. 2013;60 Suppl 2:40-44.
1981 Epub 2014/03/05. doi: 10.1111/tbed.12124.
- 1982
1983 197. Nielsen SS, Alvarez J, Bicout DJ, Calistri P, Depner K, Drewe JA, et al. Rift Valley
1984 fever - epidemiological update and risk of introduction into Europe. *EFSAJ*.
1985 2020;18(3):e06041. Epub 2020/10/07. doi: 10.2903/j.efsa.2020.6041.
- 1986
1987 198. Rolin AI, Berrang-Ford L, Kulkarni MA. The risk of Rift Valley fever virus
1988 introduction and establishment in the United States and European Union. *Emerg*
1989 *Microbes Infect*. 2013;2(12):e81. Epub 2013/12/01. doi: 10.1038/emi.2013.81.
- 1990
1991 199. Zeller H, Marrama L, Sudre B, Van Bortel W, Warns-Petit E. Mosquito-borne
1992 disease surveillance by the European Centre for Disease Prevention and Control. *Clin*
1993 *Microbiol Infect*. 2013;19(8):693-698. Epub 2013/04/24. doi: 10.1111/1469-0691.12230.
- 1994

- 1995 200. Lagerqvist N, Moiane B, Mapaco L, Fafetine J, Vene S, Falk KI. Antibodies against
1996 Rift Valley fever virus in cattle, Mozambique. *Emerg Infect Dis.* 2013;19(7):1177-1179.
1997 Epub 2013/06/15. doi: 10.3201/eid1907.130332.
- 1998
1999 201. Abakar MF, Nare NB, Schelling E, Hattendorf J, Alfaroukh IO, Zinsstag J.
2000 Seroprevalence of Rift Valley fever, Q Fever, and brucellosis in ruminants on the
2001 southeastern shore of Lake Chad. *Vector-Borne and Zoonotic Diseases.*
2002 2014;14(10):757-762. doi: 10.1089/vbz.2014.1585.
- 2003
2004 202. Consultative Group for RVF Decision Support. Decision-support tool for prevention
2005 and control of Rift Valley fever epizootics in the Greater Horn of Africa. *Am J Trop Med*
2006 *Hyg.* 2010;83(2 Suppl):75-85. doi: 10.4269/ajtmh.2010.83s2a03.
- 2007
2008 203. Shah MM, Ndenga BA, Mutuku FM, Vu DM, Grossi-Soyster EN, Okuta V, et al.
2009 High dengue burden and circulation of 4 virus serotypes among children with
2010 undifferentiated fever, Kenya, 2014-2017. *Emerg Infect Dis.* 2020;26(11):2638-2650.
2011 doi: 10.3201/eid2611.200960.
- 2012
2013 204. Vu DM, Mutai N, Heath CJ, Vulule JM, Mutuku FM, Ndenga BA, et al.
2014 Unrecognized dengue virus infections in children, western Kenya, 2014-2015. *Emerg*
2015 *Infect Dis.* 2017;23(11):1915-1917. doi: 10.3201/eid2311.170807.
- 2016
2017 205. Hortion J, Mutuku FM, Eyherabide AL, Vu DM, Boothroyd DB, Grossi-Soyster EN,
2018 et al. Acute flavivirus and alphavirus infections among children in two different areas of
2019 Kenya, 2015. *Am J Trop Med Hyg.* 2019;100(1):170-173. doi: 10.4269/ajtmh.18-0297.
- 2020
2021 206. Hertz JT, Munishi OM, Ooi EE, Howe S, Lim WY, Chow A, et al. Chikungunya and
2022 dengue fever among hospitalized febrile patients in northern Tanzania. *Am J Trop Med*
2023 *Hyg.* 2012;86(1):171-177. doi: 10.4269/ajtmh.2012.11-0393.
- 2024
2025 207. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus
2026 (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology,
2027 vectors, diagnostics and prevention. *Vet Res.* 2010;41(6):61. Epub 2010/12/29. doi:
2028 10.1051/vetres/2010033.
- 2029
2030 208. Fakour S, Naserabadi S, Ahmadi E. The first positive serological study on Rift
2031 Valley fever in ruminants of Iran. *J Vector Borne Dis.* 2017;54(4):348-352. Epub
2032 2018/02/21. doi: 10.4103/0972-9062.225840.
- 2033

2034 209. Amato L, Dente MG, Calistri P, Declich S. Integrated early warning surveillance:
2035 Achilles' Heel of One Health? *Microorganisms*. 2020;8(1). doi:
2036 10.3390/microorganisms8010084.

2037
2038 210. Hassan OA, Ahlm C, Evander M. A need for One Health approach - lessons
2039 learned from outbreaks of Rift Valley fever in Saudi Arabia and Sudan. *Infect Ecol*
2040 *Epidemiol*. 2014;4. Epub 2014/02/08. doi: 10.3402/iee.v4.20710.

2041

2042 **Supporting Information**

2043 ***Text:***

2044 **S1 Text.** Information sources and detailed scripts used in running the searches on the
2045 online databases

2046 ***Figures:***

2047 **S1 Figure.** Forest Plot for meta-analysis of the impact of butchering on odds of RVFV
2048 exposure

2049 **S2 Figure.** Forest Plot for meta-analysis of the impact of sheltering animals on odds of
2050 RVFV exposure

2051 **S3 Figure.** Forest Plot for meta-analysis of the impact of milking animals on odds of
2052 RVFV exposure

2053 ***Tables:***

2054 **S1 Table.** PRISMA checklist

2055 **S2 Table.** Listing of included studies with full citations

2056 **S3 Table.** Listing of excluded studies with full citations

2057 **S4 Table.** Listing by year of countries experiencing human or animal exposure to RVFV
2058 during 1999-2021

2059 **S5 Table.** Listing of acute human cases reported during 1999-2021. Outbreaks are
2060 indicated by year, country, region, and geographic location, with estimated population
2061 size, incidence, and case fatality rates

2062 **S6 Table.** Studies of RVFV lineage distribution based on genetic sequence analysis

2063 **S7 Table.** 1999-2021 studies of local insect vector presence and RVFV infection

2064 **S8 Table.** Studies assessing human risk factors related to animal exposures and severe
2065 RVFV disease

2066 **S9 Table.** Studies of the effects of socioeconomic status on human RVFV exposure risk

2067 **S10 Table.** Studies of the effects of occupation on human RVFV exposure risk

2068 **S11 Table.** Livestock factors related to animal RVFV exposure risk

2069 **S12 Table.** Wildlife anti-RVFV seroprevalence reported in included studies

2070 **S13 Table.** Local and national RVF surveillance systems reported in included studies

2071

Identification of RVF occurrences via publication databases and registers

Identification of RVF occurrences via other methods




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

Study name	Period	Time Interval	Statistics for each study			
			Odds ratio	Lower limit	Upper limit	p-Value
Sanderson (2020)	IEP	1985-2019	1.864	1.073	3.236	0.027
Marrama (2005)	IEP	1999	1.130	0.717	1.778	0.599
Swai (2009)	IEP	2004	3.675	0.445	30.373	0.227
Porrut (2010)	IEP	2005-2008	1.768	1.260	2.481	0.001
LaBeaud (2008)	IEP	2006	2.428	1.130	5.219	0.023
Muiruri (2015)	IEP	2006	2.643	1.252	5.578	0.011
Anyangu (2010)	Outbreak	2006-2007	1.424	1.036	1.958	0.030
Aradib (2013)	Outbreak	2007	1.378	0.724	2.623	0.329
Hassanian (2010)	Outbreak	2007	2.760	1.177	6.470	0.020
Ochieng (2015)	Postepidemic	2007	1.283	0.751	2.192	0.362
Al-Azraqi (2012)	IEP	2007-2008	0.949	0.647	1.390	0.787
Heinrich (2012)	IEP	2007-2008	1.000	0.608	1.645	1.000
LaBeaud (2011)	IEP	2009	2.324	1.173	4.603	0.016
Byomi (2015)	IEP	2009-2010	1.379	0.717	2.650	0.335
Grossi-Soyster (2017)	IEP	2009-2011	0.808	0.436	1.499	0.499
Tigoi (2015)	IEP	2009-2012	0.720	0.417	1.242	0.238
Andayi (2014)	IEP	2010-2011	1.170	0.483	2.833	0.727
Cook (2017)	IEP	2010-2012	0.452	0.147	1.384	0.164
Nakoune (2016)	IEP	2010-2012	1.866	0.704	4.945	0.210
LaBeaud (2015)	IEP	2011	1.463	1.048	2.043	0.026
Lernout (2013)	IEP	2011	1.453	0.822	2.566	0.198
Gray (2015)	IEP	2012	0.985	0.531	1.828	0.962
Sumnaye (2015)	IEP	2012	1.260	0.767	2.071	0.361
Gudo (2016)	Outbreak	2013	1.531	0.605	3.875	0.369
Bett (2019)	IEP	2013-2014	1.520	1.008	2.291	0.046
Ahmed (2018)	IEP	2014	1.432	0.719	2.851	0.307
Tigoi (2020)	IEP	2014-2015	1.670	1.168	2.387	0.005
Nyakarahuka (2018)	Outbreak	2016	2.705	1.511	4.843	0.001
Pooled OR (random effects)			1.410	1.240	1.604	0.000





Figure 7


Study name	Period	Time Interval	Statistics for each study			
			Odds ratio	Lower limit	Upper limit	p-Value
Marrama (2005)	IEP	1999	0.649	0.336	1.256	0.199
Swai (2009)	IEP	2004	3.032	0.160	57.520	0.460
LaBeaud (2008)	IEP	2006	8.335	1.959	35.460	0.004
Muiruri (2015)	IEP	2006	3.596	0.824	15.701	0.089
Anyangu (2010)	Outbreak	2006-2007	2.060	1.408	3.014	0.000
Al-Azraqi (2012)	IEP	2008	1.961	1.073	3.582	0.028
Gray (2015)	IEP	2010-2012	0.810	0.428	1.535	0.519
Sumaye (2015)	IEP	2012	1.081	0.649	1.800	0.764
Bett (2019)	IEP	2013-2014	1.908	1.044	3.488	0.036
Tigoi (2020)	IEP	2014-2015	1.380	1.009	1.888	0.044
Nyakarahuka (2018)	IEP	2016	1.194	0.684	2.084	0.533
Pooled OR (random effects)			1.457	1.092	1.944	0.010



Less likely More likely

Figure 8

Study name	Period	Time Interval	Statistics for each study			
			Odds ratio	Lower limit	Upper limit	p-Value
LaBeaud (2008)	IEP	2006	2.780	1.029	7.512	0.044
Muiruri (2015)	IEP	2006	5.320	2.491	11.361	0.000
Anyangu (2010)	Outbreak	2006-2007	3.830	1.619	9.062	0.002
Al-Azraqi (2012)	IEP	2008	11.583	6.950	19.306	0.000
Archer (2011)	Outbreak	2008	0.715	0.114	4.477	0.720
LaBeaud (2011)	IEP	2009	3.490	1.522	8.002	0.003
LaBeaud (2015)	IEP	2011	5.310	3.389	8.319	0.000
Lernout (2013)	IEP	2011	11.120	1.101	112.357	0.041
Memish (2015)	IEP	2012	3.200	1.168	8.764	0.024
Sumaye (2015)	IEP	2012	2.020	1.151	3.547	0.014
Msimang (2019)	IEP	2015-2016	1.724	0.965	3.079	0.066
Pooled OR (random effects)			3.646	2.321	5.728	0.000



Less likely More likely

Figure 9




Figure 10